document incorporate reference portion proxy statement registrant annual meeting stockholder hold incorporate reference iii annual report item business general bristolmyers squibb company refer bristolmyer squibb bms company incorporate law state delaware august bristolmyer company successor new york business start bristolmyer company change bristolmyer squibb company result merger engage discovery development licensing manufacturing marketing distribution sale biopharmaceutical product global basis year execute strategy transform generation biopharmaceutical company transformation encompass area business operation strategy divest nonpharmaceutical business implement acquisition licensing strategy know stringofpearl execute productivity transformation initiative pti divestiture include medical imaging january convatec august mead johnson december acquisition licensing transaction include kosan biosciences inc june medarex inc medarex september zymogenetics inc zymogenetics october amira pharmaceuticals inc amira september inhibitex inc inhibitex february license arrangement continue review cost structure intent maintain modernized efficient robust balance build competitive advantage secure innovative product plan future report financial operating information segmentbiopharmaceutical additional information business segment item financial statementsnote business segment information compete worldwide researchbase drug company small research company generic drug manufacturer product sell worldwide primarily wholesaler retail pharmacy hospital government entity medical profession manufacture product united states puerto rico foreign country net sale account total net sale total net sale net sales europe account total net sale net sale japan account total net sale net sale canada account total net sale product pharmaceutical product include chemicallysynthesize drug small molecule increase portion product produce biological process typically involve recombinant dna technology call biologics small molecule drug typically administer orally eg form pill tablet drug delivery mechanism biologic typically administer patient injection infusion revenue come product follow therapeutic class cardiovascular virology include human immunodeficiency virus hiv infection oncology neuroscience immunoscience metabolic pharmaceutical industry majority innovative product commercial value usually realize period product market exclusivity business focus innovative biopharmaceutical product rely patent right form regulatory protection maintain market exclusivity product european union eu country patent right form exclusivity expire generic version medicine approve market substantial rapid decline sale original innovative product discussion patent right regulatory form exclusivity intellectual property product exclusivity discussion impact generic competition business generic competition follow chart show key product year early basic exclusivity loss patent right datum exclusivity occur currently estimate occur eu japan canada sell pharmaceutical product country datum provide countrybycountry basis individual country sale significant outside eu japan canada instance basic exclusivity loss date list expiration date patent claim active ingredient drug method drug approve indication approve indication instance basic exclusivity loss date list chart expiration date datum exclusivity period situation datum exclusivity patent protection competitor seek regulatory approval submit clinical trial datum obtain marketing approval prior expiration datum exclusivity estimate market exclusivity period product casebycase basis purpose business planning length market exclusivity product impossible predict certainty complex interaction patent regulatory form exclusivity inherent uncertainty patent litigation assurance particular product enjoy market exclusivity period time appear estimate exclusivity limited estimate follow schedule present net sale key product estimate basic exclusivity loss eu japanese canadian market net sale product past currently estimate year basic exclusivity loss dollar million eu japan canada key product plavix b avaproavalide eliquis na na abilify c e reyataz f sustiva franchise g h baraclude erbitux j j sprycel k yervoy na na j j orencia j j l nulojix na na onglyzakombiglyze note currently estimate early year basic exclusivity loss include statutory extension exclusivity earn grant instance able obtain additional month exclusivity product base pediatric extension example certain instance laterexpire patent cover particular form composition drug method manufacturing method drug patent result favorable market position product product exclusivity predict assure healthcare law enact qualifying biologic product receive year datum exclusivity biosimilar enter market describe detail intellectual property product exclusivity indicate brand name product trademark own bristolmyer squibb subsidiary specific trademark ownership information find currently market product country region indicate reference eu include member states members european union year end december basic patent application file current member state list product instance date basic exclusivity loss different eu member states eu country basic patent obtain datum protection available b data exclusivity eu expire july major market europe product national patent expiring specifically claim bisulfate form clopidogrel generic alternate salt form clopidogrel bisulfate market compete plavix eu c rights commercialize abilify aripiprazole terminate right commercialize abilify eu terminate e exclusivity period base regulatory datum protection f data exclusivity eu expire g exclusivity period relate sustiva brand include exclusivity relate combination therapy composition matter patent efavirenz expire method use patent treatment hiv infection expire h exclusivity period relate sustiva brand include exclusivity relate combination therapy market exclusivity sustiva expect expire country eu data exclusivity sustiva expire eu biologic product approve biologics license application bla datum exclusivity expire patent specifically claim composition matter cetuximab active ingredient erbitux right commercialize cetuximab terminate j exclusivity period base regulatory data protection k pende patent application eu member states l data exclusivity canada expire summary indication intellectual property position product partner thirdparty manufacturing arrangement product applicable eu japan canada plavix plavix clopidogrel bisulfate platelet aggregation inhibitor approve protection fatal nonfatal heart attack stroke patient history heart attack stroke peripheral arterial disease acute coronary syndrome clopidogrel bisulfate codevelope jointly market sanofi information alliance sanofi strategic alliance collaboration item financial statementsnote alliance collaboration composition matter patent expire include pediatric extension eu regulatory datum exclusivity protection expire july major market europe plavix benefit national patent expire specifically claim bisulfate form clopidogrel generic alternative salt form clopidogrel bisulfate market compete eu obtain bulk requirement clopidogrel bisulfate sanofi thirdparty company sanofi finish product respective facility avaproavalide avaproavalide irbesartanirbesartanhydrochlorothiazide angiotensin ii receptor antagonist indicate treatment hypertension diabetic nephropathy irbesartan codevelope jointly market sanofi information alliance sanofi strategic alliance collaboration item financial statementsnote alliance collaboration composition matter patent expire march include pediatric extension country eu data exclusivity eu expire august avapro october avalide composition matter patent expire canada march irbesartan manufacture company sanofi manufacture bulk requirement irbesartan finish avaproavalide facility avalide purchase bulk requirement hydrochlorothiazide thirdparty eliquis eliquis apixaban oral factor xa inhibitor target prevention treatment venous thromboembolic vte disorder stroke prevention atrial fibrillation currently approve eu use vte prevention adult patient undergo elective hip knee replacement surgery currently registrational process eu prevention stroke systemic embolism patient atrial fibrillation apixaban discover internally alliance pfizer inc pfizer information alliance pfizer item financial statementsnote alliance collaboration composition matter patent cover apixaban expire eu expire datum exclusivity eu expire manufacture bulk requirement apixaban finish product facility abilify abilify aripiprazole atypical antipsychotic agent adult patient schizophrenia bipolar mania disorder major depressive disorder abilify pediatric use schizophrenia bipolar disorder global commercialization agreement otsuka pharmaceutical co ltd otsuka japan china taiwan north korea south korea philippines thailand indonesia pakistan egypt information arrangement otsuka strategic alliance collaboration item financial statementsnote alliance collaboration basic composition matter patent abilify term current abilify agreement expire april include grant patent term extension month pediatric extension basic composition matter patent protect aripiprazole subject patent litigation otsuka sole right enforce patent information litigation matter item financial statement legal proceeding contingency composition matter patent force germany united kingdom uk france italy netherlands romania sweden switzerland spain denmark original expiration date extend grant supplementary protection certificate country romania denmark datum exclusivity right commercialize eu expire data exclusivity canada expire obtain bulk requirement aripiprazole otsuka company otsuka finish product respective facility reyataz reyataz atazanavir sulfate protease inhibitor treatment hiv develop atazanavir worldwide license novartis pharmaceutical corporation novartis royalty pay base percentage net sale entitle promote reyataz use combination norvir ritonavir nonexclusive license agreement abbott laboratories abbott amend royalty pay base percentage net sale recently enter licensing agreement gilead sciences inc develop commercialize fixeddose combination contain reyataz gilead compound development market exclusivity reyataz expect expire canada major eu member country japan data exclusivity eu expire manufacture bulk requirement atazanavir finish product facility sustiva franchise sustiva efavirenz nonnucleoside reverse transcriptase inhibitor treatment hiv sustiva franchise include sustiva antiretroviral drug treatment hiv bulk efavirenz include combination therapy atripla efavirenz mg emtricitabine mg tenofovir disoproxil fumarate mg oncedaily single tablet drug regiman combine sustiva gilead sciences inc gilead truvada emtricitabine tenofovir disoproxil fumarate atripla complete highly active antiretroviral therapy treatment product hiv available fixeddose combination take daily fixeddose combination contain multiple medicine formulate help simplify hiv therapy patient provider information arrangement gilead strategic alliance collaboration item financial statementsnote alliance collaboration right market efavirenz canada united kingdom uk france germany ireland italy spain license merck co inc royalty base percentage net sale composition matter patent efavirenz expire method use patent treatment hiv infection expire possible additional month pediatric extension market exclusivity sustiva expect expire country eu data exclusivity sustiva expire eu company market efavirenz japan certain atripla patent subject patent litigation time patent cover efavirenz composition matter method use challenge eu patent efavirenz subject litigation netherlands germany uk information litigation matter item financial statementsnote legal proceeding contingency obtain bulk requirement efavirenz party produce finished good facility provide bulk efavirenz gilead responsible produce finished atripla product baraclude baraclude entecavir potent selective inhibitor hepatitis b virus approve fda treatment chronic hepatitis b infection baraclude discover develop internally approve market country outside include china japan eu composition matter patent expire patent subject patent litigation information litigation matter item financial statementsnote legal proceeding contingency composition matter patent expire eu japan composition matter patent expire canada uncertainty chinas exclusivity law result generic competition china market manufacture bulk requirement entecavir finish product facility erbitux erbitux cetuximab igg monoclonal antibody design exclusively target block epidermal growth factor receptor egfr express surface certain cancer cell multiple tumor type normal cell erbitux biological product approve treatment combination irinotecan treatment patient egfrexpresse metastatic colorectal cancer mcrc fail irinotecanbase regimen monotherapy patient intolerant irinotecan fda approve erbitux use treatment squamous cell carcinoma head neck specifically erbitux approve use combination radiation therapy treatment locally regionally advanced squamous cell carcinoma head neck single agent treatment patient recurrent metastatic squamous cell carcinoma head neck prior platinumbase therapy fail fda approve erbitux firstline recurrent locoregional metastatic head neck cancer combination platinum base chemotherapy fluorouracil erbitux market north america agreement imclone system incorporate imclone predecessor company imclone llc whollyowne subsidiary eli lilly company lilly share copromotion rights erbitux merck kgaa japan codevelopment cocommercialization agreement sign october imclone merck kgaa merck japan erbitux receive marketing approval japan july use treat patient advance recurrent colorectal cancer description alliance imclone strategic alliance collaboration item financial statementsnote alliance collaboration datum exclusivity expire patent specifically claim composition matter cetuximab active molecule erbitux erbitux approve fda health authority monotherapy use patent use erbitux combination antineoplastic agent approve fda combination use claim grant patent expire include grant patent term extension inventorship use patent challenge researcher yeda research development company ltd yeda pursuant settlement agreement execute announce december imclone sanofi yeda end worldwide litigation relate use patent sanofi yeda grant imclone worldwide license use patent datum exclusivity japan canada expire yeda right license use patent yeda license patent party result product competition erbitux occur unable assess extent competitive impact occur quantify impact yeda grant amgen inc amgen license use patent amgen receive fda approval market egfrproduct compete erbitux obtain finish good requirement cetuximab use north america lilly lilly manufacture bulk requirement cetuximab facility finish perform thirdparty lilly description supply agreement lilly manufacture quality assurance sprycel sprycel dasatinib multitargete tyrosine kinase inhibitor approve treatment adult phase chronic myeloid leukemia resistance intolerance prior therapy include gleevec imatinib mesylate treatment adult philadelphia chromosomepositive acute lymphoblastic leukemia resistance intolerance prior therapy fda approve sprycel treatment adult patient newly diagnose philadelphia chromosomepositive ph chronic myeloid leukemia cml chronic phase sprycel internally discover strategic alliance otsuka information alliance otsuka strategic alliance collaboration item financial statementsnote alliance collaboration patent term extension grant extend term basic composition matter patent cover dasatinib june dasatinib subject patent litigation information litigation matter item financial statementsnote legal proceeding contingency orphan drug exclusivity expire protect product generic application currently approve orphan indication eu country patent pende grant expire april exclude term extension manufacture bulk requirement dasatinib finish product facility yervoy yervoy ipilimumab biological product monoclonal antibody treatment patient unresectable inoperable metastatic melanoma ipilimumab approve fda march ema july currently study indication include lung cancer adjuvant melanoma hormonerefractory prostate cancer information research development yervoy research development yervoy discover medarex codevelope company medarex subsidiary patent cover ipilimumab composition matter currently expire eu data exclusivity expire eu obtain bulk ipilimumab thirdparty manufacturer finish product party facility orencia orencia abatacept biological product fusion protein novel immunosuppressive activity target initially adult patient moderate severe rheumatoid arthritis inadequate response certain currently available treatment abatacept available intravenous formulation begin subcutaneous formulation orencia discover develop internally series patent cover abatacept method use patent term extension grant composition matter patent extend term patent majority eu country patent covering abatacept expire apply supplementary protection certificate pediatric extension supplementary protection certificate protection protection certificate grant datum exclusivity eu expire obtain bulk abatacept thirdparty manufacturer finish product facility formulation nulojix nulojix belatacept biological product fusion protein novel immunosuppressive activity prevention kidney transplant rejection approve launch june approve eu june launch july belatacept internally discover develop patent cover belatacept composition matter expire april eu datum exclusivity expire june eu june manufacture bulk requirement belatacept finish product facility onglyza kombiglyze onglyza saxagliptin dipeptidyl peptidase inhibitor oral compound indicate treatment type diabete adjunct diet exercise kombiglyze saxagliptin metformin hydrochloride extendedrelease approve combination product indicate adjunct diet exercise improve glycemic control adult type diabete mellitus treatment saxagliptin metformin appropriate komboglyze saxagliptin metformin immediaterelease approve eu combination product indicate adjunct diet exercise improve glycemic control adult type diabete mellitus inadequately control maximally tolerate dose metformin treat combination saxagliptin metformin separate tablet document specifically note refer kombiglyze komboglyze kombiglyze onglyza internally discover company kombiglyze codevelope company astrazeneca plc astrazeneca worldwide japan codevelopment cocommercialization agreement astrazeneca saxagliptin information arrangement astrazeneca otsuka japan strategic alliance collaboration item financial statementsnote alliance collaboration patent cover saxagliptin composition matter expire march eu manufacture bulk requirement saxagliptin facility obtain bulk metformin kombiglyze party company astrazeneca finish onglyza facility company finish kombiglyze facility emerge market compete emerge market encompass regional organization emerge market regional organization comprise brazil russia india china turkey identify country significant opportunity growth emerge market characterize strong economic development rise gross domestic product grow middle class increase wealth middle class demand quality healthcare emerge market provide growth opportunity pharmaceutical industry middle decade strategy capitalize growth opportunity innovationfocuse approach approach plan develop commercialize select innovative product key high growth market tailor approach market individually emerge public health interest country good align strategy current portfolio pipeline country identify improve intellectual property protection order capitalize growth opportunity emerge market balance relate risk develop innovative pricing access strategy product accessible patient provide reasonable return investment risk market include intellectual property protection governmentmandate authorize generic currency volatility reimbursement issue government stability scale issue monitor mitigate risk extent possible research development invest heavily research development rd believe critical longterm competitiveness major rd facility princeton hopewell new brunswick new jersey wallingford connecticut pharmaceutical research development carry facility world include belgium uk india site supplement internal drug discovery development program alliance collaborative agreement agreement bring new product pipeline help remain cut edge technology search novel medicine drug development engage service physician hospital medical school research organization worldwide conduct clinical trial establish safety effectiveness new product management continue emphasize leadership innovation productivity quality strategy success research development activity concentrate biopharmaceutical research development effort follow disease area significant unmet medical need affective psychiatric disorder pain alzheimersdementia cardiovascular diabetes hepatitis hivaid oncology immunologic disorder solid organ transplant fibrotic disease continue analyze selectively pursue promising lead area addition discover develop new molecular entity look way expand value exist product new indication formulation provide additional benefit patient order new drug reach market industry practice government regulation eu foreign country provide determination drug effectiveness safety preclinical test control clinical evaluation clinical development potential new drug include phase phase ii phase iii clinical trial design specifically support new drug application particular indication assume trial successful phase clinical trial involve small number healthy patient patient suffer indicate disease test safety proper dosing phase ii clinical trial involve large patient population investigate effect efficacy optimal dosage drug candidate phase iii clinical trial conduct confirm phase ii result significantly large patient population long term provide reliable conclusive datum safety efficacy drug candidate rd process typically take thirteen year long year spend phase iii latestage development consider rd program phase iii latestage development significant rd program program include investigational compound phase iii development initial indication market product phase iii development additional indication formulation drug development time consume expensive risky average chemical compound discover pharmaceutical industry researcher prove medically effective safe approve medicine drug candidate fail stage process latestage product candidate fail receive regulatory approval accord kmr group base industry success rate approximately compound enter phase development fail achieve regulatory approval failure rate compound enter phase ii development approximately compound enter phase iii development approximately total research development expense include cost discovery research preclinical development early lateclinical development drug formulation clinical trial medical support market product proportionate allocation enterprisewide cost appropriate cost spend billion billion research development activity research development spending include payment party collaboration contract end employ approximately people rd activity include substantial number physician scientist hold graduate postgraduate degree higherskille technical personnel manage rd program portfolio basis invest resource stage research development early discovery latestage development continually evaluate portfolio rd asset ensure appropriate balance earlystage latestage program support future growth company spend latestage development program represent approximately annual rd expense individual investigational compound market product represent rd expense year list latestage investigational compound phase iii clinical trial potential indication investigational compound ultimately market product depend result clinical study competitive landscape potential product market manufacturing process necessary produce potential product commercial scale factor note assurance seek regulatory approval compound approval sought obtain assurance compound approve commercially successful stage development determine intellectual property issue patent protection available investigational compound patent coverage highlight include patent term extension grant brivanib brivanib oral small molecule dual kinase inhibitor blocks vegf receptor fgf receptor currently phase iii trial anticancer treatment potential use hepatocellular carcinoma colorectal cancer patent cover brivanib composition matter expire dapagliflozin dapagliflozin oral sglt inhibitor potential treatment diabete currently registrational process eu discover internally alliance astrazeneca patent cover dapagliflozin composition matter expire october january receive complete response letter nda dapagliflozin discussion item management discussion analysis financial condition result operationsproduct pipeline development necitumumab imcf necitumumab fully human monoclonal antibody investigate anticancer treatment discover imclone alliance company lilly phase iii trial non small cell lung cancer lilly own patent covering necitumumab composition matter expire elotuzumab elotuzumab humanized monoclonal antibody investigate anticancer treatment discover pdl biopharma facet biotech corporation facet spinoff facet subsequently acquire abbott alliance abbott phase iii trial multiple myeloma abbott own patent cover elotuzumab composition matter expire daclatasvir daclatasvir oral small molecule nsa replication complex inhibitor phase iii development treatment hepatitis c virus patent cover daclatasvir composition matter expire follow table list potential additional indication key marketed product phase iii development currently regulatory review eliquis potential indication stroke prevention atrial fibrillation vte treatment orencia potential additional indication lupus nephritis sprycel potential additional indication prostate cancer yervoy potential additional indication adjuvant melanoma prostate cancer nonsmall cell lung cancer small cell lung cancer potential additional indication firstline metastatic melanoma eu erbitux potential additional indication firstline colorectal cancer firstline secondline nonsmall cell lung cancer gastric cancer onglyza potential additional use cardiovascular risk reduction pediatric extension sustiva potential pediatric extension baraclude potential pediatric extension follow key development currently expect occur respect significant pipeline program outcome timing expect development dependent number factor include thing availability datum outcome certain clinical trial acceptance presentation certain medical meeting andor action health authority undertake obligation publicly update information result new information future event eliquis potential eu approval stroke prevention atrial fibrillation dapagliflozin potential eu approval treatment type diabete datum available phase iii study patient cardiovascular disease datum available phase iii study addon sitagliptin onglyza data available phase iii study addon metformin sulfonylurea nulojix fouryear datum available phase iii study subpopulation analyse orencia datum available headtohead study versus humira potential eu approval subcutaneous formulation phase iii start lupus nephritis phase iii start psoriatic arthritis yervoy submission dtic combination data eu ipilimumab plus vemurafenib safetyfeasibility datum available brivanib datum available phase iii study advance hepatocellular cancer erbitux potential approval firstline colorectal cancer sprycel threeyear datum line cml daclatasvir data available phase ii hepatitis c combination study strategic alliance collaboration enter strategic alliance collaboration party right develop manufacture market andor sell pharmaceutical product own party party right develop manufacture market andor sell pharmaceutical product own alliance collaboration form include licensing arrangement codevelopment comarkete agreement copromotion arrangement joint venture alliance arrangement reduce risk incur research development expense compound lead revenuegenerate product profitability alliance product generally low substantially profitability product partner profit alliance product share alliance partner assurance new alliance form actively pursue arrangement view alliance important complement discovery development activity strategic alliance arrangement party right manufacture market andor sell pharmaceutical product contain customary early termination provision typically find agreement kind generally base party material breach bankruptcy voluntary involuntary product safety concern notice require early termination generally range immediately notice day receipt notice termination immediately notice generally available party file voluntary bankruptcy petition material safety issue arise product medical riskbenefit incompatible welfare patient continue develop commercialize product termination day notice generally available involuntary bankruptcy petition file dismiss material breach party occur cure number alliance agreement permit collaborator terminate cause typically exercisable substantial advance write notice exercisable specify period time elapse collaboration agreement sign strategic alliance arrangement typically contain provision provide party right terminate alliance short notice general retain right product bring alliance party party intellectual property alliance terminate loss right product market sell pursuant strategic alliance arrangement material result operation cash flow case plavix abilify material financial condition liquidity customary pharmaceutical industry term strategic alliance arrangement generally coextensive exclusivity period vary countrybycountry basis significant current alliance arrangement currently market product investigational compound describe current marketed productsinlicensed sanofi agreement sanofi codevelopment cocommercialization avaproavalide plavix avaproavalide copromote certain country outside tradename aprovelcoaprovel comarkete certain country outside tradename karveakarvezide plavix copromote certain country outside tradename plavix comarkete certain country outside tradename iscover worldwide alliance operate framework geographic territory cover certain european asian country refer territory cover puerto rico canada australia certain latin american country refer territory b territory b manage separate set agreement plavix puerto rico products australia mexico brazil colombia argentina separate set agreement avaproavalide puerto rico territory territory partnership exist supply finish product country territory manage contract certain central expense market research development royalty country territory b structured local affiliate sanofis local affiliate comarket separate brand ie affiliate operate independently compete sell product different trademark copromote single brand ie product trademark territory comarketing country include germany spain italy irbesartan greece china clopidogrel bisulfate sell iscover karveakarvezide sanofi sell plavix aprovelcoaprovel country china retain right currently comarket iscover company sanofi copromote plavix aprovelcoaprovel france uk belgium netherlands switzerland portugal addition company sanofi copromote plavix austria italy ireland denmark finland norway sweden taiwan south korea hong kong aprovelcoaprovel certain french export country prior company sanofi copromote plavix singapore sanofi act operating partner territory own financial control interest territory ownership interest territory account investment partnership entity territory equity method recognize share result equity net income affiliate share net income partnership entity tax million million million territory b company sanofi copromote plavix avaproavalide canada puerto rico territory b countries australia mexico brazil colombia clopidogrel bisulfate argentina comarketing country act operating partner territory b majority control interest territory consolidate partnership result territory b recognize sanofis share result net earning attributable noncontrolle interest net taxis million million million recognize net sale territory b territory comarkete country billion billion billion territory partnership govern series committee enumerate function power responsibilitie territory senior committee final decisionmake authority respect territory enumerate function power responsibility jurisdiction agreement sanofi expire later respect plavix respect avaproavalide americas australia europe asia ii expiration patent exclusivity right relate product applicable territory alliance arrangement terminate sanofi affected country territory depend circumstance event voluntary involuntary bankruptcy insolvency case involuntary bankruptcy continue day order decree approving continue unstayed effect day ii material breach obligation major alliance agreement remain uncured day follow notice breach commencement diligent prosecution cure occur day notice iii deadlock senior committee render continue commercialization product impossible give country territory iv increase combine cost good royalty exceed specify percentage net selling price product v good faith determination terminate party commercialization product terminate reason patient safety case termination right agreement include provision termination relevant alliance respect applicable product applicable country territory case termination bankruptcy insolvency material breach product applicable territory termination procedure slightly different event lose right product applicable relevant country territory case bankruptcy insolvency material breach default party discussion strategic alliance sanofi item financial statementsnote alliance collaboration otsuka maintain worldwide commercialization agreement otsuka codevelop copromote abilify abilify agreement exclude certain asia pacific country april company otsuka agree extend portion commercialization manufacturing agreement expect loss product exclusivity april contractual share abilify net sale recognize company pursuant extension begin january contractual share revenue recognize company reduce uk germany france spain company receive thirdparty net sale country thirdparty customer invoice company behalf otsuka alliance revenue recognize abilify ship risk reward ownership transfer party customer exclusive right sell abilify country europe americas number countries asia country recognize net sale term abilify agreement amend purchase product otsuka perform finish manufacturing sale otsuka party customer terms extension agreement pay otsuka million amortize reduction net sale extension period unamortized balance include asset otsuka receive royalty base total net sale include cost product sell otsuka responsible expense relate commercialization abilify reimbursement net principally marketing sell administrative advertising product promotion expense abilify agreement expire april june eu countries country exclusive right sell abilify agreement expire later april loss exclusivity country begin january expect loss exclusivity april receive follow percentage annual net sale share net sale billion billion billion billion billion billion billion billion billion excess billion period otsuka responsible expense relate commercialization abilify portion abilify agreement oncology agreement describe include changeofcontrol provision acquire acquire company compete product abilify new company assume abilify agreement amend oncology agreement currently exist acquire company product compete abilify otsuka elect request acquire company choose div abilify compete product scenario abilify divest otsuka obligate acquire right abilify agreement amend price accord predetermine schedule agreement provide event generic competitor abilify option terminate abilify april amendment agreement previously amend remain force exercise option receive payment otsuka accord predetermine schedule oncology agreement terminate time ii oncology agreement continue truncated period accord predetermine schedule early termination abilify agreement immediate notice case voluntary bankruptcy ii minimum payment otsuka iii commercial sale occur month receipt necessary approval day material breach occur cure commencement cure occur day notice material breach day case involuntary bankruptcy petition file dismiss addition termination available otsuka day notice event challenge otsuka patent right marketbymarket basis event market product direct competition abilify termination expiration abilify agreement retain right abilify recognize net sale abilify billion billion addition million extension payment total upfront milestone licensing payment otsuka abilify agreement million discussion oncology agreement otsuka current market productsinternally discover discussion strategic alliance otsuka item financial statementsnote alliance collaboration lilly egfr commercialization agreement lilly lillys subsidiary imclone codevelopment copromotion erbitux necitumumab imcf canada japan information agreement respect necitumumab investigational compound developmentinlicense egfr agreement respect erbitux sale north america lilly receive distribution fee base flat rate net sale north america plus reimbursement certain royalty pay lilly company lilly share half profit loss evenly japan merck kgaa receive half profit loss japan party share royalty payable party pursuant formula set forth commercialization agreement purchase north american commercial requirement bulk erbitux lilly agreement expire erbitux north america september early termination available base material breach effective day notice material breach material breach cure commencement cure occur month notice exist significant concern regulatory patient safety issue seriously impact longterm viability product termination expiration alliance retain right erbitux share codevelopment copromotion right erbitux merck kgaa japan agreement sign october expire lilly merck kgaa merck japan lilly ability terminate agreement determine commercially unreasonable continue erbitux receive marketing approval japan july use erbitux treat patient advance recurrent colorectal cancer recognize net sale erbitux million million million discussion strategic alliance lilly item financial statementsnote alliance collaboration gilead joint venture gilead develop commercialize atripla canada europe company gilead share responsibility commercialize atripla canada eu certain european country provide fund fieldbased sale representative support promotional effort atripla gilead recognize atripla revenue canada countries europe revenue efavirenz component determine apply percentage atripla revenue approximate revenue sustiva brand recognize efavirenz revenue million million million relate atripla net sale joint venture company gilead continue terminate mutual agreement party describe event material breach party nonbreache party terminate joint venture party agree desirable practicable withdraw combination product market commercialize time generic version party component product appear market party right terminate joint venture acquire right combination product canada year terminate party continue receive percentage net sale base contribution bulk component atripla retain right product enter licensing agreement gilead develop commercialize fixeddose combination contain reyataz gileads cobicistat pharmacoenhance boost agent currently phase iii clinical trial increase blood level certain hiv medicine potentially allow pill daily dose discussion strategic alliance gilead item financial statementsnote alliance collaboration current market productsinternally discover astrazeneca january enter worldwide japan codevelopment cocommercialization agreement astrazeneca onglyza saxagliptin agreement kombiglyze codevelope astrazeneca saxagliptin agreement exclusive right develop sell onglyza japan license otsuka december describe investigational compound developmentinternally discover company astrazeneca party worldwide codevelopment cocommercialization agreement dapagliflozin describe investigational compound developmentinternally discover manufacture onglyza kombiglyze certain limited exception recognize net sale key market receive million upfront milestone licensing payment astrazeneca meet certain development regulatory milestone onglyza kombiglyze include million receive million receive receive additional million salesbased milestone meet majority cost initial development plan pay astrazeneca additional development cost generally share equally expense onglyza kombiglyze development cost net astrazenecas share research development company jointly develop clinical marketing strategy share commercialization expense profit loss equally global basis exclude japan discussion strategic alliance astrazeneca item financial statementsnote alliance collaboration otsuka simultaneously extension abilify agreement april company otsuka enter oncology agreement sprycel ixempra include japan eu market oncology territory begin collaboration fee pay otsuka annually follow percentage aggregate net sale sprycel ixempra oncology territory net sale million million million million million million billion excess billion period otsuka contribute million certain commercial operational expense relate oncology product oncology territory ii commercial operational expense relate product oncology territory excess million begin otsuka copromote sprycel japan exercise right copromote eu market begin january oncology agreement expire respect sprycel ixempra include changeofcontrol provision acquire abilify agreement describe discussion abilfy agreement otsuka current market productsinlicense discussion strategic alliance otsuka item financial statementsnote alliance collaboration pfizer company pfizer party worldwide codevelopment cocommercialization agreement eliquis anticoagulant discover study prevention treatment broad range venous arterial thrombotic condition currently approve market eu vte prevention pfizer fund development cost january fund receive million upfront milestone licensing payment pfizer date include million receive january receive additional million pfizer development regulatory milestone meet company jointly develop clinical marketing strategy eliquis share commercialization expense profit loss equally global basis discussion strategic alliance pfizer item financial statementsnote alliance collaboration investigational compound developmentinlicense lilly january company lilly restructure egfr commercialization agreement provide codevelopment cocommercialization necitumumab imcf fully human antibody currently phase iii development nonsmall cell lung cancer item management discussion analysis financial condition result operationsproduct pipeline development update phase iii trial restructure company share cost develop share profit loss commercialize necitumumab canada japan lilly maintain exclusive right necitumumab market fund development cost study japan study global study pay million lilly milestone payment approval grant canada recognize sale profit loss necitumumab lilly provide selling effort party general equally participate commercialization effort japan company lilly share commercial cost profit evenly agreement relate necitumumab continue patent expiration party agree terminate begin lilly manufacture bulk requirement assume responsibility fillfinish necitumumab abbott august grant exclusive right facet biotech corporation abbott codevelopment cocommercialization elotuzumab humanized monoclonal antibody investigate treatment multiple myeloma term agreement fund development cost elotuzumab commercialization abbott share profit loss pay tiere royalty outside solely responsible commercialization elotuzumab addition abbott receive milestone payment base certain regulatory event sale threshold achieve investigational compound developmentinternally discover astrazeneca mention worldwide codevelopment cocommercialization agreement astrazeneca dapagliflozin sglt agreement dapagliflozin study potential treatment diabete discover sglt agreement receive million upfront milestone licensing payment astrazeneca include million receive receive million development regulatory milestone dapagliflozin meet additional million salesbased milestone dapagliflozin meet majority cost initial plan pay astrazeneca additional development cost generally share equally japan astrazeneca bear substantially development cost prior approval indication expense dapagliflozin development cost net alliance partner share research development sglt agreement like saxagliptin agreement company jointly develop clinical marketing strategy share commercialization expense profit loss dapagliflozin equally global basis manufacture dapagliflozin certain limited exception recognize net sale key market respect japan astrazeneca operational cost responsibility development regulatory activity behalf collaboration relate certain trial development cost share company company jointly market product japan share commercialization expense activity split profit loss equally like rest world manufacture dapagliflozin recognize net sale japan like rest world dapagliflozin currently study phase ii clinical trial japan discussion strategic alliance astrazeneca item financial statementsnote alliance collaboration otsuka january grant otsuka exclusive right japan develop commercialize onglyza entitle receive milestone payment base certain regulatory event salesbase payment follow regulatory approval onglyza japan retain right copromote onglyza otsuka japan otsuka responsible development cost japan royalty licensing arrangement addition strategic alliance describe inlicense outlicense arrangement respect inlicense agreement novartis reyataz base current expectation respect expiration market exclusivity significant market license arrangement novartis reyataz expect expire eu japan discussion market exclusivity protection include chart show net sale key product year basic exclusivity loss occur expect occur eu japan canada product certain compound outlicense party development commercialization include obtain result acquisition zymogenetic october medarex august entitle receive milestone payment compound regulatory process royalty base product sale product commercialize intellectual property product exclusivity license number patent foreign country primarily cover product develop brand name trademark product consider overall protection patent trademark license intellectual property right material value act protect right infringement pharmaceutical industry majority innovative product commercial value usually realize period product market exclusivity product market exclusivity generally determine form intellectual property patent right hold innovator company regulatory form exclusivity innovative drug entitle patent key determinant market exclusivity brand pharmaceutical patent provide innovator right exclude practice invention relate medicine patent cover thing active ingredient use drug product pharmaceutical formulation drug delivery mechanism process intermediate useful manufacture product protection individual product extend vary period accordance expiration date patent country protection afford vary country country depend type patent scope coverage availability meaningful legal remedy country market exclusivity influence regulatory intellectual property right develop country provide certain nonpatent incentive development medicine example eu japan canada certain market regulatory intellectual property right offer incentive research medicine rare disease orphan drug medicine useful treat pediatric patient incentive extend market exclusivity period product patent term eu japan canada provide minimum period time approval new drug regulatory agency rely innovators data approve competitor generic copy datum protection certain market patent protection form market exclusivity expire datum protection particular importance regulatory form exclusivity prevent competitor gain regulatory approval prior expiration regulatory data exclusivity basis competitor safety efficacy datum drug drug identical market innovator specific aspect law govern market exclusivity datum protection pharmaceuticals vary country country follow summarize key exclusivity rule market represent significant sale united state key product protect patent vary term depend type patent filing date significant portion product patent life lose time take innovative company develop obtain regulatory approval new drug compensation lose patent term innovator depend number factor extend expiration date patent maximum term year provide extension cause patent effect year date drug approval company seek market innovative pharmaceutical submit complete set safety efficacy datum fda innovative pharmaceutical chemical company file new drug application nda medicine biological product biologic license application bla file type application file affect regulatory exclusivity right chemical product competitor seek launch generic substitute chemical innovative drug file abbreviate nda anda fda anda generic manufacturer need demonstrate bioequivalence generic substitute approve nda drug anda rely safety efficacy datum previously file innovator nda innovator company require list certain patent cover medicine fda commonly know orange book absent successful patent challenge fda approve anda innovators list patent expire innovator market product year generic manufacturer file anda allege patent list orange book innovators nda invalid infringe allegation commonly know paragraph iv certification innovator decide file patent infringement suit generic manufacturer time time anda include paragraph iv certification file respect certain product evaluate andas casebycase basis warrant file suit generic manufacturer protect patent right addition benefit patent protection certain innovative pharmaceutical product receive period regulatory exclusivity nda designate orphan drug receive seven year exclusivity orphan indication time period nda andas drug product approve orphan use company earn month additional exclusivity drug specific clinical trial conduct write request fda study use medicine treat pediatric patient submission fda prior loss basic exclusivity medicine approve nda receive type regulatory data protection innovative chemical pharmaceutical entitle year regulatory data protection competitor file fda approval generic substitutes innovators patent challenge describe generic manufacturer file anda fourth year fiveyear datum protection period pharmaceutical drug product contain active ingredient previously approve nda approve new formulation drug new indication basis new clinical trial receive year datum protection formulation indication biologic product healthcare legislation enact regulatory approval biosimilar version biological product obtain abbreviate path abbreviate path approval biosimilar product healthcare legislation significantly affect regulatory data exclusivity biological product legislation provide regulatory mechanism allow fda approval biologic drug similar generic copy innovative drug basis extensive datum require bla legislation create approval pathway biosimilar version biological product previously exist innovative biological product long receive essentially unlimited regulatory data exclusivity exist prior creation regulatory path biosimilar version law innovator market biological product year biosimilar manufacturer file application approval biosimilar version innovator product application approval biosimilar file year approval innovator product qualify innovative biological product receive year regulatory exclusivity mean fda approve biosimilar version year innovative biological product approve fda law provide mechanism innovator enforce patent protect innovative biological product biosimilar applicant challenge patent patent litigation begin early year innovative biological product approve fda increase likelihood generic biosimilar challenge innovators intellectual property increase risk loss innovator market exclusivity generic company increasingly seek challenge innovator basic patent cover major pharmaceutical product second statutory regulatory provision limit ability innovator company prevent generic biosimilar drug approve launch patent litigation ongoing result development possible predict length market exclusivity particular product certainty base solely expiration relevant patent current form regulatory exclusivity european union patent pharmaceutical product generally enforceable eu extended compensate patent term lose regulatory review process extension grant countrybycountry basis primary route use obtain marketing authorization pharmaceutical product eu centralized procedure procedure compulsory certain pharmaceutical product particular biotechnological process available certain new chemical compound product company seek market innovative pharmaceutical product centralized procedure file complete set safety datum efficacy datum marketing authorization application maa european medicine agency ema ema evaluates maa provide recommendation european commission ec ec approve deny maa possible new chemical product obtain marketing authorization eu mutual recognition procedure application single member state member state approve pharmaceutical product national procedure applicant submit approval mutual recognition procedure member state obtain marketing authorization approval company obtain pricing reimbursement pharmaceutical product typically subject member state law certain eu country process place simultaneously product market eu country process complete company market new product pricing reimbursement procedure month year complete eu product marketing authorization file octobernovember subject regime year innovator receive community authorization medicinal product generic company file marketing authorization application product health authority market authorization application approve generic company commercialize product year elapse initial marketing authorization grant innovator possible extension year available innovator year marketing authorization obtain additional indication significant clinical benefit comparison exist treatment product file prior octobernovember year period datum protection centralize procedure period year mutual recognition procedure depend member state contrast patent eu list regulatory authority generic version pharmaceutical product approve data protection expire regardless innovator hold patent cover drug possible innovator seek enforce patent generic competitor market product european patent system opposition procedure generic manufacturer challenge validity patent cover innovator product month grant general eu law treat chemicallysynthesize drug biologicallyderive drug respect intellectual property datum protection addition relevant legislation annexe relate biologic medicinal product ema issue guideline outline additional information provide biosimilar product know generic biologic order review application marketing approval japan japan medicines new chemical entity generally afford year datum exclusivity approve indication dosage patent pharmaceutical product enforceable generic copy receive regulatory approval datum exclusivity patent expiration patent japan extended compensate patent term lose regulatory review process general japanese law treat chemicallysynthesize biologicallyderive drug respect intellectual property market exclusivity canada canada medicines new chemical entity generally afford year datum exclusivity approve indication dosage patent pharmaceutical product enforceable generic copy receive regulatory approval datum exclusivity patent expiration currently unlike canada patent term restoration compensate patent term lose regulatory review process canada biologics generally treat chemicallysynthesized product respect patent right regulatory exclusivity health canada issue draft guidance outline additional information provide subsequent entry biologic know biosimilar product generic biologic order review application marketing approval rest world country outside eu japan canada wide variety legal system respect intellectual property market exclusivity pharmaceutical develop country utilize system similar eu eg switzerland develop country adopt patent law andor regulatory exclusivity law develop country formally adopt law order comply world trade organization wto commitment take step implement law meaningful way enforcement wto action long process government assurance outcome assess likely future market exclusivity innovative drug develop country account formal legal right political factor marketing distribution customer promote appropriate use product directly healthcare professional provider doctor nurse practitioner physician assistant pharmacist technologist hospital pharmacy benefit manager pbms manage care organization mcos provide information appropriate use product consumer directtoconsumer print radio television advertising addition sponsor general advertising educate public innovative medical research discussion regulation promotion marketing pharmaceutical government regulation price constraint sale marketing organization explain approve use risk benefit product medical professional work gain access health authority pbm mco formulary list recommend approve medicine product include medicare plan reimbursement list provide information clinical profile product marketing prescription pharmaceutical limit approve use particular product continue develop scientific datum information product provide information response unsolicite inquiry doctor medical professional manage care organization operation include marketing sale organization organization market distinct group product support sale force typically base particular therapeutic area physician group sale force focus sell new product introduce promotion physician increasingly target specialist key primary care physician product sell principally wholesaler less extent directly distributor retailer hospital clinic government agency pharmacie gross sale large pharmaceutical wholesaler percentage total gross sale follow mckesson corporation cardinal health inc amerisourcebergen corporation business inventory management agreement ima substantially direct wholesaler distributor customer allow monitor wholesaler inventory level require wholesaler maintain inventory level month demand ima expire december subject certain termination provision number define market outside establish scale distributor model medically necessary drug available patient continue marketing authorization trademark product contract service fullservice distributor provide distribution logistic regulatory pharmacovigilance sale advertising promotion certain product contract clearly define term condition service provide supply firm order period monitor inmarket sale forecast ensure reasonable inventory level product sale maintain fully continuously meet demand product distributor territory responsibility sale distributorbase market represent company net sale competition market compete generally broad base highly competitive compete worldwide researchbase drug company small research company limit therapeutic focus generic drug manufacturer important competitive factor include product efficacy safety ease use price demonstrate costeffectiveness marketing effectiveness product label customer service research development new product process sale product impact new study indicate competitor product safe effective treat disease particular form disease product sale impact additional labeling requirement relate safety convenience impose product fda similar regulatory agency different country competitor introduce new product process therapeutic cost advantage product subject progressive price reduction decrease volume sale generic competition big competitive challenge face generic pharmaceutical manufacturer eu regulatory approval process exempt generic costly timeconsuming clinical trial demonstrate safety efficacy allow generic manufacturer rely safety efficacy innovator product result generic pharmaceutical manufacturer typically invest far research development researchbase pharmaceutical company price product significantly lower brand product accordingly brand product lose market exclusivity normally face intense price competition generic form product expiration loss market exclusivity product lose major portion sale product short period time rate sale decline product expiration exclusivity vary country general decline market rapid develop country observe rapid decline number eu country decline develop country tend rapid develop country rate sale decline expiration exclusivity historically influence product characteristic example drug large patient population eg prescribed key primary care physician tend experience rapid decline drug specialized area medicine eg oncology drug complex manufacture eg sterile injectable product usually experience slow decline simple manufacture certain country outside patent protection weak nonexistent compete generic version shortly launch innovative product addition generic pharmaceutical company introduce generic product exclusivity expire resolution relate patent litigation information market exclusivity intellectual property product exclusivity believe longterm competitive position depend success discover develop innovative costeffective product serve unmet medical need ability manufacture product efficiently market effectively highly competitive environment manage care organization growth mcos major factor healthcare marketplace half population participate version manage care mco include medical insurance company medical plan administrator healthmaintenance organization medicare prescription drug plan alliance hospital physician physician organization organization consolidate few large entity enhance purchasing strength importance successfully compete business mcos demonstrate product offer medical benefit cost advantage compare form care new product introduce compete product market product later develop competitor note generic drug exempt costly timeconsuming clinical trial demonstrate safety efficacy lower cost brandname drug mcos focus primarily immediate cost drug favor generic reason government encourage use generic alternative brandname drug healthcare program law generally allow case require pharmacist substitute generic drug rate government procedure essentially equivalent brandname drug substitution prescribe physician expressly forbid exclusion product formulary lead sharply reduce usage mco patient population consequently pharmaceutical company compete aggressively product include possible company compete inclusion base unique feature product great efficacy well patient ease use few effect low overall cost therapy important factor product demonstrate few therapeutic advantage compete inclusion base primarily price generally universally successful major product include mco formulary government regulation price constraint pharmaceutical industry subject extensive global regulation regional country state local agency federal food drug cosmetic act fdc act federal statute regulation state statute regulation law regulation foreign government govern vary degree test approval production labeling distribution postmarket surveillance advertising dissemination information promotion product lengthy process laboratory clinical testing datum analysis manufacture development regulatory review necessary require governmental approval extremely costly significantly delay product introduction give market promotion marketing manufacturing distribution pharmaceutical product extensively regulate major world market addition operation subject complex federal state local foreign environmental occupational safety law regulation anticipate law regulation affect manufacture sale current product introduction new product continue require substantial scientific technical effort time expense significant capital investment particular importance fda jurisdiction virtually activity impose requirement cover testing safety effectiveness manufacturing labeling marketing advertising postmarkete surveillance product case fda requirement increase time money necessary develop new product bring market fda mandate drug manufacture package label conformity current good manufacturing practice cgmp establish fda comply cgmp regulation manufacturer continue expend time money effort production recordkeeping quality control ensure product meet applicable specification requirement ensure product safety efficacy fda periodically inspect drug manufacturing facility ensure compliance applicable cgmp requirement failure comply statutory regulatory requirement subject possible legal regulatory action suspension manufacturing seizure product voluntary recall product adverse experience use product report fda result imposition market restriction label change product removal product approval withdraw compliance regulatory requirement maintain problem concern safety efficacy occur follow approval federal government extensive enforcement power activitie pharmaceutical manufacturer include authority withdraw product approval commence action seize prohibit sale unapproved noncomplye product halt manufacture operation compliance cgmp impose seek injunction voluntary recall civil monetary criminal penalty restriction prohibition sale withdrawal approval product market materially adversely affect business financial condition result operation cash flow marketing authorization product subject revocation applicable governmental agency addition modification enhancement approve product change manufacturing location circumstance subject additional fda approval receive subject lengthy application process distribution pharmaceutical product subject prescription drug marketing act pdma fdc act regulate activity federal state level pdma implement regulation state permit require registration manufacturer distributor provide pharmaceutical manufacturer distributor place business state state permit adopt regulation limit distribution product sample license practitioner pdma impose extensive licensing personnel recordkeeping packaging quantity labeling product handle facility storage security requirement intend prevent sale pharmaceutical product sample product diversion fda amendment act impose additional obligation pharmaceutical company delegate enforcement authority fda area drug safety key element legislation fda authority require company conduct postmarkete safety study drug impose certain drug labeling change relate safety mandate risk mitigation measure education healthcare provider restrict distribution medicine require company publicly disclose datum clinical trial prereview television advertisement marketing practice pharmaceutical manufacturer subject federal state healthcare law protect integrity government healthcare program office inspector general department health human service oig oversee compliance applicable federal law connection payment product government fund program primarily medicaid medicare law include federal antikickback statute criminalize offer value induce recommendation order purchase product service reimburse government healthcare program oig issue series guidance segment healthcare industry include compliance program guidance pharmaceutical manufacturer oig guidance include recommendation pharmaceutical manufacturer minimum adhere phrma code voluntary industry code marketing practice subscribe phrma code implement compliance program address requirement set forth oig guidance compliance healthcare law failure comply healthcare law subject administrative legal proceeding include action federal state government agency action result imposition civil criminal sanction include fine penalty injunctive remedy impact materially adversely affect business financial condition result operation cash flow subject jurisdiction federal state regulatory enforcement department agency federal trade commission department justice department health human service license drug enforcement agency procure produce control substance subject possible administrative legal proceeding action organization action result imposition civil criminal sanction include fine penalty injunctive administrative remedy activity outside subject regulatory requirement govern testing approval safety effectiveness manufacturing labeling marketing product regulatory requirement vary country country fda approval approval ema obtain product approval product comparable regulatory authority country outside eu case obtain prior marketing product country approval process rigorous country country time require approval long shorter require approval country assure product approve country market outside operate environment governmentmandate costcontainment program government place restriction physician prescription level patient reimbursement emphasize great use generic drug andor enact acrosstheboard price cut method cost control eu countries example government regulate price new product launch direct price control international price comparison control profit andor reference pricing market uk germany government set pricing restriction launch pricing freedom subsequently limited operation profit price control plan uk operation reference price system germany company face significant delay market access new product mainly france spain italy belgium year elapse new medicine available national market additionally member states eu regularly impose new additional cost containment measure pharmaceutical recent year italy example impose mandatory price decrease existence price differential eu different national pricing reimbursement law lead significant parallel trade flow internationally healthcare industry subject governmentimposed regulation authorize price price control continue impact net sale march government enact healthcare reform legislation sign law patient protection affordable care act hr reconciliation bill contain package change healthcare bill legislation make extensive change current system healthcare insurance benefit intend broaden coverage reduce cost bill significantly change americans receive healthcare coverage pay significant impact company particular company pharmaceutical industry healthcare relate industry include bms experience continue experience additional financial cost certain change business new healthcare law implement example minimum rebate medicaid drug sale increase percent percent medicaid rebate extend drug riskbase medicaid manage care plan addition extend discount certain critical access hospital cancer hospital cover entity require expansion b drug pricing program public health service act require provide percent discount brandname drug patient fall medicare coverage gap refer donut hole pay annual nontaxdeductible fee federal government base allocation market share brand prior year sale certain government program include medicare medicaid department veterans affairs department defense tricare market outside operate environment governmentmandate costcontainment program regulatory body group exert downward pressure pricing pricing freedom limited uk instance operation profit control plan germany operation reference price system company face significant delay market access new product year elapse drug approval new medicine available country federal state government pursue direct method reduce cost drug pay participate state government medicaid program certain qualify federal state government program discount rebate provide participate state local government entity participate government program specify discount certain government entity significant department defense department veterans affair entity receive minimum discount base define nonfederal average manufacturer price purchase program participate provide discount outpatient medicine purchase certain specify entity section b public health service act discussion rebate program item management discussion analysis financial condition result operationsnet sale critical accounting policy source availability raw material general purchase raw material supply require production product open market product purchase raw material supply source source available single source approve source available require obtain raw material supply particular source attempt possible mitigate raw material supply risk inventory management alternative source strategy discussion source manufacture quality assurance discussion particular product manufacture quality assurance meet expect product demand operate manage manufacturing network include thirdparty contract manufacturer inventory relate thereto manner permit improve efficiency maintain flexibility reallocate manufacturing capacity pharmaceutical production process complex highly regulate vary widely product product give shift add manufacturing capacity lengthy process require significant capital outofpocket expenditure regulatory approval maintain operate flexible manufacturing network consist internal external resource minimize unnecessary product transfer inefficient use manufacturing capacity discussion regulatory impact manufacturing government regulation price constraint pharmaceutical manufacturing facility locate puerto rico france italy ireland japan mexico china require significant ongoing capital investment maintenance compliance increase regulatory requirement addition product line change year expect continue modification exist manufacturing network meet complex processing standard require newly introduce product include biologic biologic manufacturing involve complex process traditional pharmaceutical operation february purchase acre site locate large scale multiproduct bulk biologic manufacturing facility deven massachusetts construction deven massachusetts facility begin early substantially complete submit site regulatory approval early expect fda complete review application end year rely party manufacture supply certain active ingredient necessary manufacture product include plavix baraclude avalide reyataz abilify erbitux sustiva franchise orencia yervoy onglyza kombiglyze maintain stable supply product variety action include inventory management maintenance additional quantity material possible design provide reasonable level ingredient hold thirdparty supplier manufacturing operation interrupt additional protection case step maintain approve backup source available example rely capacity devens massachusetts facility capacity available thirdparty contract manufacturer manufacture orencia thirdparty manufacturer rely exist future product unable maintain stable supply product operate sufficient capacity meet order requirement comply government regulation manufacturing pharmaceutical meet complex processing requirement biologic business performance prospect negatively impact additionally thirdparty supplier experience extend plant shutdown substantial unplanned increase demand suspension manufacture regulatory reason experience interruption supply certain product product shortage production resume expand connection divestiture license arrangement distribution agreement certain product certain circumstance enter agreement agree supply product party addition liability arise failure supply product agreement arrangement require invest facility production nonstrategic product result additional regulatory filing obligation cause interruption manufacturing product success depend great measure customer confidence quality product integrity datum support safety effectiveness product quality arise total commitment quality part operation include research development purchasing facility planning manufacturing distribution maintain qualityassurance procedure relate quality integrity technical information production process control production process involve detailed specification ingredient equipment facility manufacturing method process packaging material labeling perform test stage production process final product ensure product meet regulatory requirement standard test involve chemical physical chemical analyse microbiological testing combination analyse quality control provide business unitsite quality assurance group monitor exist manufacturing procedure system subsidiary thirdparty supplier environmental regulation facility operation subject extensive foreign law regulation relate environmental protection human health safety include govern discharge pollutant air water use management disposal hazardous radioactive biological material waste cleanup contamination pollution control permit require operation permit subject modification renewal revocation issue authority environment health safety group monitor operation world provide overview regulatory requirement oversee implementation standard compliance incur operating capital cost matter ongoing basis expend approximately million million million capital project undertake specifically meet environmental requirement believe substantial compliance applicable environmental health safety requirement permit require operation incur additional cost include civil criminal fine penalty cleanup cost thirdparty claim property damage personal injury violation liabilitie law current facility operation year time operator facility generate store dispose substance waste consider hazardous federal state andor foreign environmental law include comprehensive environmental response compensation liability act cercla result soil groundwater certain facility contaminate require significant expenditure investigate control remediate contamination case provide compensation andor restoration damage natural resource currently involve investigation remediation current facility identify potentially responsible party prp applicable law environmental condition approximately waste disposal reprocess facility operate party investigation andor remediation activity ongoing face liability cercla federal state foreign law entire cost investigation remediation contaminate site natural resource damage regardless fault ownership time disposal release addition certain site bear remediation responsibility pursuant contractual obligation generally thirdparty operator site involve multiple prps liability expect apportion base nature hazardous substance dispose party site number financially viable prps additional information matter item financial statementsnote legal proceeding contingency employee december employ approximately people foreign operation significant operation outside conduct subsidiary distributor geographic breakdown net sale table caption geographic area item financial statementsnote business segment information discussion net sale geographic area item management discussion analysis financial condition result operationsnet sale international operation subject certain risk inherent conduct business abroad include limited currency fluctuation possible nationalization expropriation price exchange control counterfeit product limitation foreign participation local enterprise restrictive governmental action international business subject governmentimpose constraint include law price reimbursement use product depend direction change relative dollar foreign currency value increase decrease report dollar value net asset result operation change foreign exchange rate net favorable impact growth rate revenue predict certainty future change foreign exchange rate effect attempt mitigate impact operational mean financial instrument discussion item quantitative qualitative disclosure market risk item financial statementsnote financial instrument bristolmyer squibb website internet website address wwwbmscom website available free charge annual quarterly current report include amendment report soon reasonably practicable electronically file material furnish material securities exchange commission sec information relate corporate governance bristolmyer squibb include standard business conduct ethic code ethic senior financial officer code business conduct ethic director collectively code corporate governance guideline information concern executive committee board director include board committee committee charter transaction bristolmyers squibb security director executive officer available website investorscorporate governance caption print stockholder request waiver code director executive officer material amendment code business conduct ethic director code ethic senior financial officer post promptly website information relate stockholder service include dividend reinvestment plan direct deposit dividend available website investorsstockholder service caption incorporate reference certain information part proxy statement annual meeting stockholder sec allow disclose important information refer manner refer information proxy statement annual meeting stockholder annual report available website investorssec filing caption march item risk factor factor describe significantly negatively affect business prospect financial condition operating result credit rating cause trading price common stock decline additional risk uncertainty presently know risk currently consider immaterial impair operation face intense competition pharmaceutical manufacturer include innovative medicine lowerprice generic product competition include lowerpriced generic version product major challenge internationally face patent expiration increasingly aggressive generic competition competition include new product develop competitor low price superior performance safety feature competitive product ii technological advance patent attain competitor iii earlierthanexpecte competition generic company iv clinical study result relate product competitor product v business combination competitor major customer experience limited market access real perceive difference value proposition product compare compete product depend certain key product net sale cash flow earning market exclusivity plavix avaproavalide expect expire march respectively derive majority revenue earning key product net sale plavix approximately billion represent approximately total net sale net sale abilify approximately billion represent approximately total net sale product reyataz sustiva franchise baraclude billion net sale reduction net sale key product significantly negatively impact net sale cash flow earning plavix topselle product net sale approximately billion expect plavix lose exclusivity rapid precipitous material decline plavix net sale reduction net income operate cash flow avaproavalide net sale million lose patent protection march expect experience precipitous decline avaproavalide net sale unable support grow currently market product successfully launch newly approve product advance latestage pipeline manage cost effectively loss exclusivity plavix avaproavalide material negative impact result operation cash flow financial condition possible lose market exclusivity product early expect pharmaceutical biotechnology industry majority innovative product commercial value usually realize period market exclusivity country market exclusivity expire generic version product approve market usually substantial rapid decline product sale rate decline vary country therapeutic category market exclusivity product base patent right andor certain regulatory form exclusivity scope patent right vary country country dependent availability meaningful legal remedy country failure obtain patent intellectual property right limitation use loss right material country include certain eu member state basic patent protection product exist certain country historically offer right obtain certain type patent andor licensor file market absent relevant patent protection product datum exclusivity period expire generic version product approve market generic clopidogrel bisulfate certain eu markets addition prior expiration datum exclusivity competitor seek regulatory approval submit clinical trial datum obtain marketing approval manufacturer generic product increasingly seek challenge patent expire key patent cover key product abilify atripla baraclude sprycel currently subject patent litigation case generic manufacturer choose launch generic product risk expiration applicable patent andor final resolution relate patent litigation length market exclusivity product difficult predict certainty assurance particular product enjoy market exclusivity period time appear estimate disclose example unexpectedly lose exclusivity plavix canada face increase pricing pressure restriction abroad manage care organization institutional purchaser government agency program negatively affect net sale profit margin pharmaceutical product continue subject increase price pressure restriction eu region world include limit rule practice manage care organization institutional governmental purchasers ii judicial decision governmental law regulation relate medicare medicaid healthcare reform include medicare prescription drug improvement modernization act patient protection affordable care act iii potential impact importation restriction legislative andor regulatory change pharmaceutical reimbursement medicare formularie product pricing general iv delay gain reimbursement andor reduction reimbursement amount country government mandate costcontainment program eg major european market japan canada v developments technology andor industry practice directly indirectly impact reimbursement policy practice thirdparty payer vi limited market access real perceive difference value proposition product compare compete product business result operation affect continue affect healthcare reform legislation describe item management discussion analysis financial condition result operationsexecutive summarybusiness environment patient protection affordable care act hr reconciliation bill contain package change healthcare bill sign law march bill include provision reduce net sale increase cost increase medicaid rebate expand medicaid program additional prescription drug discount certain patient medicare nontaxdeductible annual fee pharmaceutical company thing continue experience significant financial cost certain change business implementation healthcare reform law annual eps impact healthcare reform increase incremental impact associate medicare coverage gap annual pharmaceutical company fee healthcare reform law create regulatory mechanism allow approval biologic drug similar generic copy innovative drug basis extensive datum basis bla foreign law regulation negatively affect net sale profit margin subject new government law regulation additional healthcare reform initiative federal state level country include additional mandatory discount ii change fda foreign regulatory approval process cause delay approve prevent approval new product iii change corporate tax regulation include propose budget deficit reduction package include limit foreign tax credit tax certain tax haven tax certain excess income transfer intellectual property limiting disallow certain deduction operate interest expense change rule earning repatriation eliminate certain tax credit change tax rate phase currently available tax benefit certain foreign country change tax law iv new law regulation judicial governmental decision affect pricing drug reimbursement receivable repayment access marketing jurisdiction v change intellectual property law vi matter compulsory license alter protection afford product legal regulatory change negatively affect business operating result financial condition company emerge legislation reduce federal budget deficit enact reduce operating result change product label market product result certain study release product approve potentially negative impact product sale label pharmaceutical product change regulatory authority time include product market year change result additional datum postmarkete study headtohead trial report adverse event patient healthcare professional study identify biomarker objective characteristic indicate particular response product therapy study produce important additional information product new information add product label affect safety risk andor efficacy benefit profile product additional information study identify portion patient population non responsive medicine labeling change base study limit patient population change label plavix erbitux year ago study provide additional information sponsor sponsor competitor insurance company government institution manage care organization influential scientist investigator interested party additional safety efficacy information study assist healthcare provider identify good patient population product negative impact sale product extent patient population product labeling limited additionally certain study result especially headtohead trial affect product formulary listing adversely affect sale experience difficulty delay manufacture distribution sale product experience difficulty delay inherent manufacture distribution sale product seizure recall product force closing manufacture plant ii supply chain continuity include result natural manmade disaster facility critical supplier vendor failure failure vendor supplier comply current good manufacturing practice applicable regulation quality assurance guideline lead manufacturing shutdown product shortage delay product manufacture iii manufacturing quality assurancequality control supply problem governmental approval delay consolidation rationalization manufacture facility sale closure certain site iv failure sole source single source supplier provide necessary raw material supply finish good extend period time impact continuous supply v failure thirdparty manufacturer supply finish product time vi construction regulatory approval delay relate new facility expansion exist facility include intended support future demand biologic product vii manufacturing distribution problem include limit manufacturing capacity regulatory requirement change type product produce biologic physical limitation business interruption impact continuous supply experience difficulty delay development commercialization new product experience difficulty delay development commercialization new product include inherent risk uncertaintie develop product compound product appear promise development fail reach market expect optimal timeframe fail reach market approve product extension additional indication number reason include efficacy safety concern delay denial necessary regulatory approval delay difficulty produce product commercial scale level excessive cost manufacture product ii failure enter successfully implement optimal alliance applicable development andor commercialization product iii failure maintain consistent scope variety promise latestage product iv failure product achieve maintain commercial viability addition observe recent trend fda delay approval decision new product announce action date month long regulatory approval delay especially common product expect risk evaluation mitigation strategy address significant riskbenefit issue inability bring product market significant delay expect approval relate launch date new product potentially negative impact net sale earning result significant impairment inprocess research development intangible asset january bms collaboration partner astrazeneca receive complete response letter nda dapagliflozin complete response letter request additional datum allow well assessment benefitrisk profile dapagliflozin include clinical trial datum ongoing study require information new clinical trial finally natural manmade disaster sabotage research development labs compound library andor loss key molecule intermediary negatively impact product development cycle legal matter adverse outcome negatively affect business currently involve future involved lawsuit claim proceeding government investigation preclude delay commercialization product adversely affect operation profitability liquidity financial condition possible insurance recovery available legal matter include intellectual property dispute ii sale marketing practice internationally iii adverse decision litigation include product liability commercial case iv recall withdrawal pharmaceutical product force closing manufacture plant v failure fulfill obligation supply contract government customer result liability vi product pricing promotional matter vii lawsuit claim assert investigation violation security antitrust federal state pricing consumer protection antibribery foreign corrupt practice act uk antibribery act law viii environmental health safety matter ix tax liability assurance increase scope matter additional lawsuit claim proceeding investigation future assurance matter material adverse impact rely party meet contractual regulatory obligation rely supplier vendor partner include alliance pharmaceutical company manufacture development commercialization product party meet contractual regulatory obligation relation arrangement failure critical party meet obligation andor development significant disagreement factor materially disrupt ongoing commercial relationship prevent optimal alignment party activity material adverse impact addition party violate allege violate law regulation include foreign corrupt practice act performance obligation possible suffer financial reputational harm negative outcome include possible legal consequence dependent outsourcing arrangement dependent thirdparty provider certain outsource service include certain research development capabilitie certain financial outsource arrangement certain human resource function information technology activity system thirdparty provider locate market subject political risk corruption infrastructure problem natural disaster addition country specific privacy datum security risk give current legal regulatory environment failure service provider meet obligation adequately deploy business continuity plan event crisis andor development significant disagreement natural manmade disaster factor materially disrupt ongoing relationship provider negatively affect operation failure execute business strategy adversely impact growth profitability year transform diversified pharmaceutical relate healthcare product company biopharmaceutical company focus innovative product area high unmet medical need focus sustain business building foundation future plavix large selling product lose exclusivity plan achieve foundation continue support grow currently market product advance latestage pipeline manage cost maintain improve financial strength strong balance sheet cash position risk associate strategy able consistently replenish innovative pipeline internal research development transaction party competition major pharmaceutical company acquisition product licensing opportunity intense eliminate opportunity make expensive able locate suitable acquisition target license partner reasonable price successfully execute transaction additionally change structure operation revenue cost efficiency result major transaction acquisition divestiture merger alliance restructuring strategic initiative result great expect cost long expect complete encounter difficulty include need regulatory approval appropriate inability expand product portfolio new product maintain competitive cost basis materially adversely affect future result operation unable support grow currently market product successfully execute launch newly approve product advance latestage pipeline manage cost effectively experience significant material negative impact result operation financial condition addition failure hire retain personnel right expertise experience operation critical business function adversely impact execution business strategy increasingly dependent information technology system infrastructure face certain risk include cybersecurity datum leakage risk increasingly dependent information technology system infrastructure significant breakdown invasion destruction interruption system employee authorize access system unauthorized person negatively impact operation risk experience business interruption theft information reputational damage result cyber attack infiltration datum center datum leakage confidential information internally thirdparty provider invest heavily protection datum information technology reduce risk assurance effort prevent breakdown breach system adversely affect business expansion social medium platform present new risk challenge inappropriate use certain medium vehicle cause brand damage information leakage lead legal implication improper collection andor dissemination personally identifiable information addition negative post comment social network web site seriously damage reputation disclosure nonpublic company sensitive information external medium channel lead information loss structured process place secure protect information identify new point entry social medium continue expand present new challenge adverse change global regional economic condition continue adverse effect profitability business high government debt burden continue high unemployment rate rise price include related commodity energy low economic growth adversely affect commercial activity europe region world business government austerity measure decline economic activity market business adversely affect demand pricing product reduce revenue earning cash flow passthrough effect result significant financial instability customer distributor alliance partner supplier critical vendor service provider counterpartie certain financial instrument marketable security derivative future pension plan funding requirement continue sensitive global economic condition relate impact equity market change foreign currency exchange rate interest rate material adverse effect result operation significant operation outside revenue operation outside account approximately revenue expose fluctuation foreign currency exchange rate borrowing expose change interest rate expose economic factor control illegal distribution sale party counterfeit version product steal product negative impact reputation business party illegally distribute sell counterfeit version product meet rigorous manufacturing testing standard product undergo patient receive counterfeit drug risk number dangerous health consequence reputation business suffer harm result counterfeit drug sell brand addition theft inventory warehouse plant intransit properly store sell unauthorized channel adversely impact patient safety reputation business item b unresolved staff comment item property world headquarter locate park avenue new york ny lease approximately square foot floor space lease approximately propertie country manufacture product worldwide location own manufacturing location aggregate square foot floor space geographic area follow december number location square feet united states europe japan asia pacific canada latin america middle east africa emerge market total portion manufacturing location property own lease research development administration storage distribution information property item businessmanufacture quality assurance item legal proceeding information pertain legal proceeding find item financial statementsnote legal proceeding contingency incorporate reference ia executive officer registrant list information executive officer february executive officer elect board director initial term continue board meeting follow annual meeting stockholder elect oneyear term successor elect executive officer serve pleasure board director current position age employment history past year lamberto andreotti executive vice president president worldwide chief executive officer director pharmaceutical division company executive vice member senior management team president chief operating officer worldwide pharmaceutical division company executive vice president chief operating officer president chief operating officer director company present chief executive officer director company charle bancroft vice president finance worldwide pharmaceutical executive vice president chief financial officer division company member senior management team chief financial officer company present executive vice president chief financial officer company giovanni caforio md senior vice president oncology worldwide president pharmaceuticals pharmaceutical division company member senior management team senior vice president oncology global commercialization senior vice president oncology immunoscience global commercialization present president pharmaceuticals joseph c caldarella vice president corporate controller senior vice president corporate controller present senior vice president corporate controller beatrice cazala president emea worldwide medicine international executive vice president commercial operation president emea asia pacific worldwide medicine member senior management team international president global commercialization president europe senior vice president commercial operation president global commercialization europe emerge market present executive vice president commercial operations john e celentano president health care group division company senior vice president human resource public senior vice president strategy productivity affairs philanthropy transformation member senior management team president emerge market asia pacific present senior vice president human resource public affair philanthropy francis cuss mb bchir frcp senior vice president discovery exploratory clinical senior vice president research development development member senior management team present senior vice president research research development brian daniels md senior vice president global clinical development research senior vice president global development development division company medical affair research development present senior vice president global development medical member senior management team affair research development sandra leung vice president corporate secretary acting general general counsel corporate secretary counsel member senior management team present general counsel corporate secretary louis schmukler senior vice president pharmaceutical operating unit wyeth president technical operation senior vice president specialtybiotechnology operating member senior management team unit pfizer present president technical operations elliott sigal md phd executive vice president chief scientific officer president executive vice president chief scientific officer research development president research development director present executive vice president chief scientific officer member senior management team president research development director company paul von autenrie vice president chief information officer senior vice president chief information officer present senior vice president chief information officer member senior management team ii item market registrant common stock stockholder matter market price bristolmyer squibb common preferred stock trade new york stock exchange nyse symbol bmy quarterly summary high low market price present high low high low common quarter second quarter quarter fourth quarter prefer quarter second quarter quarter fourth quarter fourth quarter quarter observable trade company prefer stock holder common stock number record holder common stock december number record holder base actual number holder register book date include holder share street name person partnership association corporation entity identify security position listing maintain depository trust company dividend board director declare follow dividend share pay quarter indicate common prefer quarter second quarter quarter fourth quarter december board director declare quarterly dividend share common stock pay february shareholders record january board director declare quarterly dividend share prefer stock payable march shareholders record february issuer purchase equity security follow table summarize surrender repurchase equity security month period end december total number share approximate dollar value average price purchase share total number pay publicly announce purchase period share purchaseda sharea plan programsb plan programsb dollar million share datum january february march month end march april june month end june july august september month end september october november december month end december month end december difference total number share purchase total number share purchase publicly announce program share common stock withhold employee restrict stock award order satisfy applicable tax withholding obligation b announce board director authorize purchase billion common stock repurchase program expiration date expect place year item select financial datum year financial summary amount million share datum income statement dataa net sale continue operation net earning net earning attributable noncontrolle interest net earning attributable bms net earning common share attributable bms basic diluted average common share outstanding basic dilute dividend pay bms common preferred stock dividend declare common share financial position datum december cash cash equivalent marketable securitiesb total asset longterm debt equity discussion item affect comparability result year item management discussion analysis financial condition result operationsnon gaap financial measure b marketable security include current noncurrent asset item management discussion analysis financial condition result operation executive summary bristolmyers squibb company refer bristolmyer squibb bms company global biopharmaceutical company mission discover develop deliver innovative medicine help patient prevail disease license manufacture market distribute sell pharmaceutical product global basis continue execute stringofpearl strategy acquisition amira pharmaceuticals inc amira september inhibitex inc inhibitex february collaboration agreement enter year yervoy ipilimumab launch united states european union eu treatment adult patient unresectable inoperable metastatic melanoma launch subcutaneous formulation orencia abatacept nulojix belatacept eu prevention organ rejection adult patient receive kidney transplant eliquis apixaban eu prevention venous thromboembolic event vte adult patient undergo hip knee replacement surgery announce main result aristotle trial eliquis compare warfarin significantly reduce risk stroke systemic embolism new drug application nda marketing authorization application maa eu eliquis accept review january receive complete response letter food drug administration fda nda dapagliflozin complete response letter request additional clinical datum ongoing study require information new clinical trial highlight follow table summary financial highlight year end december dollar million share datum net sale total expense earning continue operation income taxis provision income taxis effective tax rate net earning continue operation attributable bms gaap nongaap dilute earning share continue operation attributable bms gaap nongaap cash cash equivalent marketable security nongaap financial measure include nongaap earning relate eps information adjust exclude specify item represent certain cost expense gain loss item impact comparability financial result detail list specify item information reconciliation nongaap financial measure nongaap financial measure business environment business primarily conduct pharmaceuticalbiotechnology industry highly competitive subject numerous government regulation competitive factor significantly affect sale product include product efficacy safety price demand competition cost effectiveness marketing effectiveness market access product label quality control quality assurance manufacturing operation research development new product successfully compete business healthcare industry demonstrate product offer medical benefit cost advantage new product introduction compete product market therapeutic category addition potential competition new product competitor introduce future manufacture brand product price high generic product generic competition lead challenge globally pharmaceuticalbiotechnology industry majority innovative product commercial value usually realize market exclusivity period long protect patent subject new compete product form generic brand exclusivity loss lose major portion product sale short period time competitor seek approval biological product biologic license application bla file safety efficacy datum address challenge biologics manufacturing involve complex process costly pharmaceutical operation healthcare legislation enact describe fully abbreviate path regulatory approval generic version biological product path approval biosimilar product healthcare legislation significantly affect regulatory data exclusivity biological product legislation provide regulatory mechanism allow regulatory approval biologic drug similar generic copy innovative drug basis extensive datum require bla possible time reasonably assess impact biosimilar legislation company globally healthcare industry subject governmentimposed regulation authorize price price control continue impact net sale march government enact healthcare reform legislation sign law patient protection affordable care act hr reconciliation bill contain package change healthcare bill legislation extensive change healthcare insurance benefit system intention broaden coverage reduce cost bill significantly change americans receive healthcare coverage pay significant impact company particular company pharmaceutical industry healthcare relate industry include bms experience continue experience additional financial cost certain change business healthcare law provision effective example minimum rebate medicaid drug sale increase percent percent medicaid rebate extend drug riskbase medicaid manage care plan additional provision impact financial result go effect january percent discount brandname drug patient medicare coverage gap refer donut hole second annual nontaxdeductible pharmaceutical company fee payable federal government base allocation market share brand prior year sale certain government program include medicare medicaid department veterans affairs department defense tricare annual eps impact healthcare reform increase net sale reduce million result new discount associate medicare coverage gap marketing selling administrative expense increase million new annual non taxdeductible pharmaceutical company fee incremental impact associate medicare coverage gap annual pharmaceutical company fee aggregate financial impact healthcare reform year depend number factor include limited pende implementation guidance potential change sale volume eligible new rebate discount fee impact cost sharing arrangement certain alliance partner positive impact net sale expect increase number people healthcare coverage potentially occur future expect early market outside operate environment governmentmandate costcontainment program regulatory body group exert downward pressure pricing pricing freedom limited uk instance operation profit control plan germany operation reference price system european country continue fiscal challenge healthcare payer include government agency reduce expect continue reduce cost healthcare action directly indirectly impose additional price restriction company face significant delay market access new product year elapse drug approval new medicine available country growth manage care organization mcos significantly impact competition surround healthcare industry mco seek reduce healthcare expenditure participant make volume purchase enter longterm contract negotiate discount pharmaceutical provider market potential create large pool participant marketing prescription drug mcos important strategy company compete inclusion mco formulary generally successful key product include believe development manage care industry include continued consolidation continue downward pressure price pharmaceutical biotechnology production process complex highly regulate vary widely product product shift add manufacturing capacity lengthy process require significant capital expenditure regulatory approval biologic manufacturing involve complex process traditional pharmaceutical operation biologic large percentage product portfolio continue supply arrangement thirdparty manufacturer substantial investment increase internal capacity produce biologic commercial scale investment new stateoftheart manufacturing facility production biologic devens massachusetts submit site regulatory approval expect fda complete review application end year maintain competitive position market strive uphold position dependent success discover develop deliver innovative costeffective product help patient prevail disease subject number significant pende lawsuit claim proceeding investigation possible time reasonably assess final outcome investigation litigation additional discussion legal matter item financial statementsnote legal proceeding contingency strategy past year transform company focus biopharmaceutical company transformation encompass area business operation focus portfolio product yielded continue yield substantial cost saving cost avoidance turn increase financial flexibility advantage attractive market opportunity arise expect lose exclusivity large product plavix time expect rapid precipitous material decline plavix net sale reduction net income operate cash flow expect decline avaproavalide irbesartanirbesartan hydrochlorothiazide net sale immediately follow loss exclusivity march event norm industry company experience loss exclusivity product recognize fact continue focus sustain business building robust foundation future plan achieve foundation continue support grow currently market product advance pipeline maintain improve financial strength overall strategy build company continue expand biologic capability rely significantly small molecule strongest reliable starting point discover potential new medicine large molecule biologic derive recombinant dna technology increasingly important currently pipeline compound biologic key marketed product include yervoy strategy include focus certain emerge market acquisition licensing strategy know stringofpearl optimize mature brand portfolio managing cost strategy emerge market develop commercialize innovative product key highgrowth market tailor approach market continue focus core biopharmaceutical maximize value mature brand portfolio complete follow strategic transaction acquire amira pharmaceutical inc amira smallmolecule pharmaceutical company focus fibrotic disease enter agreement ono pharmaceuticals co ltd ono expand territorial right develop commercialize antibody pd investigational cancer immunotherapy create strategic alliance codevelopment cocommercialization orencia japan obtain exclusive worldwide right ambrx inc ambrx research develop commercialize novel biologic diabete heart disease obtain exclusive worldwide right innate pharma sa innate develop commercialize iph novel immuneoncology biologic phase development enter clinical collaboration roche evaluate utility yervoy combination roche investigational braf inhibitor vermurafenib treat patient specific type metastatic melanoma announce licensing agreement gilead sciences inc gilead development commercialization new fixeddose combination contain reyataz gileads cobicistat treatment hiv enter strategic partnership aslan pharmaceutical development bms investigational small molecule inhibitor meet receptor tyrosine kinase treatment solid tumor enter clinical collaboration agreement tibotec pharmaceutical tibotec janssen pharmaceutical company evaluate utility daclatasvir bms investigational nsa replication complex inhibitor combination tibotec investigational ns protease inhibitor tmc treatment chronic hepatitis c virus agree codevelop bms preclinical small molecule inhibitor cholesteryl ester transfer protein cetp potentially raise hdl good cholesterol level help prevent cardiovascular disease simcere pharmaceutical group simcere enter clinical collaboration pharmasset inc pharmasset wholly own subsidiary gilead evaluate utility declatasvir bms nsa replication complex inhibitor combination psi pharmasset nucleotide polymerase inhibitor treatment chronic hepatitis c virus subsequently announce addition additional treatment arm phase iia trial february acquire inhibitex inc inhibitex clinicalstage biopharmaceutical company focus develop product treat hepatitis c virus infectious disease product pipeline development manage research development rd program portfolio basis invest resource stage research development early discovery latestage development continually evaluate portfolio rd asset ensure appropriate balance earlystage latestage program support future growth consider rd program enter phase iii development significant program constitute latestage development pipeline phase iii development program include investigational compound phase iii development initial indication market product phase iii development additional indication formulation spend program represent approximately annual rd expense individual investigational compound market product represent rd expense year expect latestage development program market latestage development program rd program potentially impact revenue earning year follow recent significant development market product latestage pipeline yervoy monoclonal antibody treatment patient unresectable inoperable metastatic melanoma currently study indication include lung cancer adjuvant melanoma hormonerefractory prostate cancer july company announce european commission approve yervoy treatment adult patient previouslytreate advanced melanoma june company announce th annual meeting american society clinical oncology result study evaluate newlydiagnose patient treat yervoy mgkg combination dacarbazine versus dacarbazine significant improvement overall survival patient treat yervoy plus dacarbazine versus receive dacarbazine high estimate survival rate observe year year year patient treat yervoy plus dacarbazine versus receive dacarbazine june company announce enter clinical collaboration roche evaluate utility yervoy combination roche investigational braf inhibitor vermurafenib treat patient specific type metastatic melanoma march fda approve yervoy treatment patient newly diagnose previouslytreate unresectable inoperable metastatic melanoma eliquis oral factor xa inhibitor indicate eu prevention venous thromboembolic event vte adult patient undergo elective hip knee replacement surgery development stroke prevention patient atrial fibrillation af prevention treatment venous thromboembolic disorder strategic alliance pfizer inc pfizer november fda accept review nda eliquis prescription drug user fee act pdufa goal date decision fda march validate application eu november company pfizer announce result phase iii adopt trial evaluate eliquis versus enoxaparin acutely ill medical patient meet primary efficacy outcome superiority enoxaparin endpoint vte vterelate death august european society cardiology congress company pfizer announce main result phase iii aristotle trial evaluate eliquis compare warfarin prevention stroke systemic embolism patient atrial fibrillation risk factor stroke eliquis compare warfarin significantly reduce risk stroke systemic embolism percent major bleeding percent mortality percent june company pfizer announce phase iii aristotle trial eliquis meet primary efficacy objective noninferiority warfarin combine outcome stroke ischemic hemorrhagic unspecified type systemic embolism addition eliquis meet key secondary endpoint superiority efficacy international society thrombosis haemostasis isth major bleeding compare warfarin company pfizer announce european commission approve eliquis prevention vte adult patient undergo elective hip knee replacement surgery february company pfizer publish result averroe study eliquis new england journal medicine study demonstrate patient af expect demonstrate unsuitable vitamin k antagonist therapy warfarin eliquis statistically superior aspirin reduce composite stroke systemic embolism significant increase major bleed fatal bleed intracranial bleed significant difference risk hemorrhagic stroke eliquis aspirin study result show eliquis demonstrate superiority secondary efficacy endpoint reduce composite stroke systemic embolism myocardial infarction vascular death patient af compare aspirin nulojix fusion protein novel immunosuppressive activity prevention kidney transplant rejection june company announce fda european commission approve nulojix prophylaxis organ rejection adult patient receive kidney transplant new datum nulojix present american transplant congress european society organ transplantation esot meeting include threeyear outcome benefit phase iii study nulojix vs cyclosporine kidney transplant recipients ii threeyear safety profile nulojix kidney transplant recipient benefit benefitext study iii renal function year kidney transplant recipient switch cyclosporine tacrolimus nulojix result longterm extension phase ii study iv threeyear outcome donor type phase iii study nulojix vs cyclosporine kidney transplantation benefit benefitext dapagliflozin oral sglt inhibitor treatment diabete strategic alliance astrazeneca plc astrazeneca january fda issue complete response letter nda dapagliflozin complete response letter request additional clinical datum allow well assessment benefitrisk profile dapagliflozin include clinical trial datum ongoing study require information new clinical trial company work closely fda determine appropriate step dapagliflozin application ongoing discussion health authority europe countrie application procedure december company astrazeneca announce international diabetes federation world diabete conference result phase iii study dapagliflozin show reduction blood sugar level glycosylate hemoglobin level hbac see week dapagliflozin exist glimepiride sulfonylurea therapy compare placebo add glimepiride maintain week adult type diabete patient take dapagliflozin add glimepiride maintain reduction fast plasma glucose level postprandial glucose total body weight november company astrazeneca present metaanalysis clinical datum cardiovascular safety adult patient type diabete show dapagliflozin associate unacceptable increase cardiovascular risk relative comparator pool clinical program july fdas endocrinologic metabolic drug advisory committee vote efficacy safety datum provide substantial evidence support approval nda dapagliflozin adjunct diet exercise improve glycemic control adult type diabete mellitus june american diabetes association meeting company astrazeneca present result phase iii clinical study examine dapagliflozin add metformin maa dapagliflozin validate ema maa submission dapagliflozin file december orencia fusion protein indicate rheumatoid arthritis november american college rheumatology annual scientific meeting company present new data orencia clinical trial support recent fda approval subcutaneous formulation orencia reduction sign symptom adult moderate severe arthritis datum present include longterm immunogenicity datum intravenous formulation longterm safety datum rheumatoid arthritis result phase iiiii study lupus nephritis august maa subcutaneous formulation orencia validate review european medicine agency july fda approve subcutaneous formulation orencia treatment adult moderate severe rheumatoid arthritis onglyzakombiglyze saxagliptinsaxagliptin metformin treatment type diabete strategic alliance astrazeneca december fda approve onglyza use combination therapy insulin metformin improve blood sugar adult patient type diabete november european commission approve kombiglyze know eu komboglyze treatment type diabete november european commission approve onglyza use combination therapy insulin metformin improve blood sugar glycemic control adult patient type diabete september th european association study diabete annual meeting company astrazeneca announce result investigational phase iiib clinical study report onglyza mg add insulin metformin maintain glycemic control glycosylate hemoglobin level hbac adult patient type diabete compare addition placebo weeks june company astrazeneca announce result investigational phase iiib clinical study report onglyza mg add insulin metformin significantly reduce blood sugar level glycosylate hemoglobin level hbac week compare treatment placebo add insulin metformin company astrazeneca announce state food drug administration approve onglyza china february company astrazeneca announce european commission approve label update onglyza treatment adult type diabete moderate severe renal impairment make onglyza dipeptidyl peptidase ddp inhibitor europe available type diabete patient moderate severe renal impairment february company astrazeneca announce fda approve inclusion datum clinical study update onglyza prescribe information adult type diabete label update provide evidence use renally impair adult type diabete comparison glipizide onglyza patient take metformin sprycel dasatanib oral inhibitor multiple tyrosine kinase indicate treatment adult chronic accelerate myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy include gleevec imatinib meslylate firstline treatment adult sprycel strategic alliance otsuka pharmaceuticals inc otsuka september chinas state food drug administration approve sprycel treatment adult chronic accelerate lymphoid myeloid chronic myeloid leukemia resistance intolerance prior therapy imatinib june regulatory authority japan approve use sprycel firstline treatment chronic myeloid leukemia june company otsuka announce fiveyear follow datum sprycel mg daily demonstrate overall survival patient chronicphase myeloid leukemia resistant intolerant gleevec result announce th annual meeting american society clinical oncology plavix platelet aggregation inhibitor alliance sanofi january company sanofi announce fda grant company additional sixmonth period exclusivity market plavix exclusivity plavix schedule expire baraclude entecavir oral antiviral agent treatment chronic hepatitis b november nd annual meeting american association study liver disease company announce result week study phase iiib clinical trial show statistical difference baraclude monotherapy mg daily baraclude mg daily plus tenovir mg daily treatmentnave adult patient hbeagpositive hbeagnegative chronic hepatitis b compensate liver disease february european commission approve baraclude treatment hepatitis b adult patient decompensate liver disease abilify aripiprazole antipsychotic agent treatment schizophrenia bipolar mania disorder major depressive disorder strategic alliance otsuka february company otsuka announce fda approve abilify adjunct mood stabilizer lithium valproate maintenance treatment bipolar disorder european approval use receive january reyataz atazanavir sulfate protease inhibitor treatment hiv february fda approve update labeling reyataz include dose recommendation hivinfecte pregnant woman hiv combination therapy treatment recommend adult dose reyataz mg boost mg ritonavir achieve minimum plasma concentration hour postdose trimester pregnancy comparable observe historically hivinfecte adult post partum period atazanavir concentration increase dose adjustment necessary patient monitor month delivery erbitux cetuximab monoclonal antibody design exclusively target block epidermal growth factor receptor express surface certain cancer cell multiple tumor type normal cell currently indicate use colorectal cancer head neck cancer erbitux alliance eli lilly company lilly november fda approve erbitux combination platinumbase chemotherapy fluorouracil line treatment recurrent locoregional metastatic squamous cell carcinoma head neck necitumumab imcf investigational anticancer agent strategic alliance lilly february company lilly announce enrollment stop phase iii inspire study necitumumab firstline treatment advanced nonsmall cell lung cancer trial evaluate addition necitumumab combination alimta pemetrexed injection cisplatin decision stop enrollment follow independent datum monitor committee dmc recommendation new recently enrol patient continue treatment trial safety concern related thromboembolism experimental arm study dmc note patient receive cycle necitumumab appear low ongoing risk safety concern patient choose remain trial inform additional potential risk investigator continue assess patient cycle determine potential benefit treatment necitumumab continue study phase iii trial name squire study evaluating necitumumab potential treatment different type lung cancer call squamous nonsmall cell lung cancer combination gemzar gemcitabine hcl injection cisplatin independent dmc recommend trial continue safety concern observe brivanib investigational anticancer agent january american society clinical oncology asco gastrointestinal cancer symposium national cancer institute canada ncic clinical trial group australasian gastrointestinal trial group agitg present result phase iii randomize trial cetuximab plus brivanib alaninate placebo patient metastatic chemotherapy refractory kra wild type colorectal carcinoma primary endpoint improvement overall survival meet trial december company report phase iii briskps brivanib study hcc patient risk post sorafenib clinical trial patient hepatocellular carcinoma hcc liver cancer fail intolerant sorafenib meet primary endpoint improve overall survival versus placebo result operation net sale composition change net sale follow year end december vs vs net sale analysis change analysis change total foreign total foreign dollar million change volume price exchange change volume price exchange united states europe japan asia pacific canada latin america middle east africa emerge market na na na na total total sale growth period attributable high volume high average net selling price favorable foreign exchange reflect continue growth key product offset decline sale avaproavalide mature brand region international sale plavix change net sale attribute price result high average net selling price plavix period abilify partially offset reduction contractual share abilify net sale reduction high rebate discount result healthcare reform legislation change net sale attribute volume reflect recent launch yervoy increase demand key product partially offset decrease prescription demand avaproavalide plavix expect continue decrease result expect loss exclusivity product change net sale attribute volume reflect increase demand key product key product discussion sale key product net sales europe increase favorable foreign exchange sale growth key product partially offset low sale certain mature brand divestiture generic competition generic competition plavix avaproavalide net sales europe decrease unfavorable foreign exchange previously mention generic competition offset sale growth key product net sale period negatively impact continue fiscal challenge european country healthcare payer include government agency reduce expect continue reduce cost healthcare action directly indirectly impose additional price reduction measure include limited mandatory discount rebate price reduction restrictive measure net sale japan asia pacific canada increase period primarily high demand baraclude sprycel net sale increase recent launch orencia japan approval sprycel line indication japan impact partially offset generic competition avaproavalide canada low sale mature brand generic competition divestiture period emerge market region comprise brazil russia india china turkey net sale growth period drive increase sale volume primarily china brazil partially offset pricing pressure turkey russia high net sale china primarily attributable baraclude certain mature brand period high net sale brazil primarily attributable reyataz abilify single country outside contribute total net sale general business seasonal information pharmaceutical prescriber demand reference table estimated endus demand set forth comparison change net sale estimate total prescription growth retail mail order customer certain key product nonu net sale categorize base location customer recognize revenue net grosstonet sale adjustment describe critical accounting policy contractual share abilify atripla sale reflect net grosstonet sale adjustment gross sale reconciliation gross sale net sale significant category grosstonet sale adjustment follow year end december dollar millions gross sale grosstonet sale adjustment chargeback related government program cash discount manage healthcare rebate contract discount medicaid rebate sale return adjustment total grosstonet sale adjustment net sale activity end balance significant category grosstonet sale reserve adjustment follow manage healthcare chargeback rebate related government cash contract medicaid sale dollar million program discount discount rebate return adjustment total balance january provision relate sale current period provision relate sale prior period return payment impact foreign currency translation balance december provision relate sale current period provision relate sale prior period return payment impact foreign currency translation balance december grosstonet sale adjustment percentage worldwide gross sale primarily function gross sale trend change sale mix contractual legislative discount rebate grosstonet sale adjustment increase chargeback relate government program increase period primarily reimbursement price increase excess current inflation rate manage healthcare rebate contract discount increase discount patient medicare coverage gap medicaid rebate increase change minimum rebate drug sale extension medicaid rebate rate drug sell riskbase medicaid manage care organization medicaid rebate continue increase year impact expansion medicaid rebate drug riskbase medicaid manage care plan high average net selling price plavix high medicaid channel sale increase unpaid rebate time increase lag payment attribute government agency administrative delay sale return include million reduction million return reserve establish connection recall certain lot avalide low return expect sale return attributable sale expect increase result loss exclusivity plavix avaproavalide key product net sale key product represent total net sale follow table present international net sale key product percentage change prior period foreign exchange impact compare prior period commentary detail reason significant variance key product provide change attributable year end december change foreign exchange dollar million vs vs vs vs key product plavix clopidogrel bisulfate nonus avaproavalide irbesartanirbesartanhydrochlorothiazide nonus abilify aripiprazole nonus reyataz atazanavir sulfate nonus sustiva efavirenz franchise nonus baraclude entecavir nonus erbitux cetuximab nonus sprycel dasatinib nonus yervoy ipilimumab na na na na na na na na na na na na nonus na na na na na na orencia abatacept nonus nulojix belatacept na na na na na na na na na na na na nonus na na na na na na onglyzakombiglyze saxagliptinsaxagliptin metformin nonus mature product nonus change excess plavix platelet aggregation inhibitor alliance sanofi net sale increase period primarily high average net selling price estimate total prescription demand decrease respectively expect rapid material decline plavix sale follow loss exclusivity plavix sale depend erosion rate generic competition wholesale retail inventory level expect return international net sale continue impact launch generic clopidogrel product eu australia negative impact net sale eu comarketing country australia equity net income affiliate relate share sale partnership sanofi europe asia expect continue erosion plavix net sale eu impact international net sale equity net income affiliate expect erosion international net sale follow recent loss exclusivity plavix canada item financial statementsnote legal proceeding contingenciesplavix litigation discussion plavix exclusivity litigation eu avaproavalide know eu aprovelkarvea angiotensin ii receptor blocker treatment hypertension diabetic nephropathy sanofi alliance net sale decrease market share loss subsequent avalide supply shortage quarter associate previously report recall total estimate prescription demand decrease decrease net sale partially offset high average net selling price reduction previously establish reserve estimate return connection recall certain lot avalide low actual return expect expect rapid material decline avaproavalide sale follow loss exclusivity march international net sale decrease low demand include generic competition certain eu markets canada international net sale decrease primarily decrease overall demand generic competition eu reduce supply avalide addition million sale return adjustment record result avalide recall estimate total prescription demand decrease eliquis oral factor xa inhibitor prevention vte adult patient undergo elective hip knee replacement surgery development prevention treatment venous thromboembolic disorder stroke prevention patient atrial fibrillation strategic alliance pfizer eliquis approve eu vte prevention launch limited number eu country begin net sale million abilify antipsychotic agent treatment schizophrenia bipolar mania disorder major depressive disorder strategic alliance otsuka net sale increase high overall demand average net selling price partially offset reduction contractual share net sale estimate total prescription demand increase net sale decrease primarily reduction contractual share net sale high medicaid rebates healthcare reform decrease partially offset high average net selling price overall demand estimate total prescription demand increase period international net sale increase high demand reyataz protease inhibitor treatment hiv net sale relatively flat increase primarily high demand estimate total prescription demand increase period international net sale increase primarily high demand sustiva franchise nonnucleoside reverse transcriptase inhibitor treatment hiv include sustiva antiretroviral drug bulk efavirenz include combination therapy atripla efavirenz mgemtricitabine mgtenofovir disoproxil fumarate mg product sell joint venture gilead net sale increase primarily high average net selling price higher estimate total prescription demand net sale increase primarily higher estimate total prescription demand period international net sale increase primarily high demand baraclude oral antiviral agent treatment chronic hepatitis b net sale period increase primarily high demand erbitux monoclonal antibody design exclusively target block epidermal growth factor receptor express surface certain cancer cell multiple tumor type normal cell currently indicate use colorectal cancer head neck cancer erbitux strategic alliance lilly sell exclusively net sale increase primarily high demand include demand approval erbitux firstline treatment recurrent locally regionally advanced metastatic squamous cell carcinoma head neck net sale decrease primarily low demand low average net selling price sprycel oral inhibitor multiple tyrosine kinase indicate treatment adult chronic accelerate myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy include gleevec imatinib meslylate firstline treatment adult philadelphia chromosomepositive chronic myeloid leukemia chronic phase sprycel strategic alliance otsuka net sale period increase primarily high demand average net selling price demand positively impact approval sprycel firstline treatment adult patient newly diagnose philadelphia chromosomepositive chronic myeloid leukemia chronic phase eu fourth quarter yervoy monoclonal antibody treatment patient unresectable inoperable metastatic melanoma yervoy launch second quarter limited number eu country fourth quarter net sale million defer patient infusion return policy establish quarter orencia fusion protein indicate adult patient moderate severe rheumatoid arthritis inadequate response currently available treatment methotrexate antitumor necrosis factor therapy net sale increase period primarily high demand include launch orencia subcutaneous formulation high average net selling price international net sale increase period primarily high demand nulojix fusion protein novel immunosuppressive activity target prevention kidney transplant rejection nulojix approve launch eu onglyzakombiglyze treatment type diabete onglyzakombiglyze increase period primarily high overall demand launch country kombiglyze launch fourth quarter mature product include product lose exclusivity major market counter brand international net sale decrease continued generic erosion certain product low average net selling price europe year year impact rationalization divestiture nonstrategic product portfolio low demand certain counter product estimate prescription change datum provide report include information retail mail order channel reflect product demand channel hospital home health care clinic federal facility include veteran administration hospital longterm care datum provide wolter kluwer health wk sprycel base source prescription audit december sprycel demand base information nextgeneration prescription service ngps version national prescription audit provide ims health im datum product respective service provider recordkeeping projection process subject inherent limitation estimate base sampling include margin error prior december sprycel demand calculate base datum obtain ims health im national sale perspective audit management believe information im national prescription audit accurately reflect subscriber demand trend versus pill datum im national sale perspective audit prior year sprycel datum restate reflect information im national prescription audit continuously seek improve quality estimate prescription change amount ultimate patientconsumer demand review calculation methodology employ analyze internal thirdparty datum expect continue review refine methodology process calculation estimate monitor quality party datum calculation calculate estimate total prescription change weightedaverage basis reflect fact mail order prescription include great volume product supply compare retail prescription mail order prescription typically reflect day prescription retail prescription typically reflect day prescription calculation derive multiply mail order prescription datum factor approximate add retail prescription believe calculation estimate total prescription change base weightedaverage approach provide superior estimate total prescription demand retail mail order channel use methodology internal demand report estimate endus demand follow table set forth key product sell year end december change report net sales year ii estimate total prescription change retail mail order channel calculate base thirdparty datum weightedaverage basis iii month inventory hand wholesale distribution channel year end december december change change month net sale total prescription hand dollar millions plavix avaproavalide abilify reyataz sustiva franchisea baraclude erbituxb na na na sprycel yervoybc na na na na na na na na orenciab na na na nulojixbc na na na na na na na na onglyzakombiglyze na na sustiva franchise total revenue include sale sustiva revenue bulk efavirenz include combination therapy atripla month hand relate sustiva b erbitux yervoy orencia nulojix parenterally administer product prescriptionlevel datum physician write prescription product c yervoy nulojix launch second quarter onglyza launch quarter kombiglyze launch fourth quarter onglyza month inventory hand december kombiglyze month inventory hand december support initial product launch change excess pursuant securities exchange commission sec consent order describe sec consent order monitor level inventory hand wholesaler distribution channel outside direct customer distribution channel obligate disclose product level inventory excess month hand expect demand subject de minimis exception estimate level inventory distribution channel excess month hand product material date indicate product estimate level inventory distribution channel excess month hand december international product estimate level inventory distribution channel excess month hand september nulojix month inventory hand support initial product launch inventory nominal expect work time demand new product increase post launch dafalgan analgesic product sell principally europe month inventory hand direct customer compare month inventory hand december level inventory hand primarily order pattern pharmacist france fervex cold flu product month inventory hand internationally direct customer compare month inventory hand december level inventory hand decrease high demand france russia luftal antacid product month inventory hand internationally direct customer compare month inventory hand december level inventory hand primarily government purchasing pattern brazil product sell exclusively wholesaler distributor generally determine month hand estimate inventory level product hand outmovement provide large wholesaler account approximately total gross sale product provide distributor factor influence estimate include generic competition seasonality product wholesaler purchase light increase wholesaler list price new product launch new warehouse opening wholesaler new customer stocking wholesaler addition estimate calculate thirdparty datum impact recordkeeping process business outside significantly direct customer limit information direct customer product level inventory correspond outmovement information reliability thirdparty demand information available vary widely case direct customer product level inventory ultimate patientconsumer demand outmovement datum exist available develop variety methodology estimate datum include factor historical sale direct customer thirdparty market research datum relate prescription trend endus demand accordingly rely variety method estimate direct customer product level inventory calculate month hand factor affect estimate include generic competition seasonality product direct customer purchase light price increase new product launch new warehouse opening direct customer new customer stocking direct customer expect direct customer purchase governmental bidding situation information require estimate month hand direct customer distribution channel nonus business year end december available prior file annual report disclose product level inventory excess month hand expect demand subject de minimis exception quarterly report form q expense net sale change vs vs cost product sell marketing sell administrative advertising product promotion research development provision restructure litigation expense net equity net income affiliate incomeexpense total expense change excess cost product sell cost product sell consist material cost internal labor overhead own manufacturing site thirdparty processing cost supply chain cost settlement foreign currency forward contract hedge forecast intercompany inventory purchase transaction essentially cost manage primarily global manufacturing organization refer technical operation discovery royalty attribute license product connection alliance profit sharing payment certain collaboration amortization acquire develop technology cost business combination milestone payment occur regulatory approval include cost product sell cost product sell vary period result product mix particularly result royalty profit sharing expense connection alliance price inflation cost attribute rationalization manufacturing site result accelerated depreciation impairment charge strand cost addition change foreign currency provide volatility give high percentage total cost denominate foreign currency increase cost product sell period primarily attributable high sale volume result additional royalty collaboration fee profit sharing expense unfavorable foreign exchange cost product sell percentage net sale reflect favorable product mix marketing sell administrative marketing sell administrative expense consist salary benefit cost thirdparty professional marketing fee outsource fee shipping handling cost expense attribute product manufacturing cost research development expense expense manage regional commercialization function global function finance law information technology human resource increase primarily attribute annual pharmaceutical company fee million unfavorable foreign exchange high marketing cost support new launch key product less extent high bad debt expense eu charitable funding information technology expense decrease primarily attribute reduction sale relate activity certain key product coincide respective life cycle prior year impact million funding payment bms foundation reduction abilify sale force otsuka establish sale force promotion abilify sprycel ixempra reduce project standardization implementation cost role new accounting human resource relate system overall efficiency gain continuous improvement initiative advertising product promotion advertising product promotion expense consist related media sample direct consumer program decrease primarily attribute low spending promotion certain key product coincide product life cycle otsukas reimbursement certain abilify sprycel ixempra advertising product promotion expense partially offset increase spend onglyza launch pipeline product research development research development expense consist salary benefit cost thirdparty grant fee pay clinical research organization supply facility cost total research development expense include cost discovery research preclinical development early lateclinical development drug formulation clinical trial medical support market product proportionate allocation enterprisewide cost appropriate cost expense include thirdparty licensing fee typically pay upfront regulatory contractual milestone meet certain expense share alliance partner base contractual agreement expense manage global research development organization approximately billion total spend attribute development activity remainder attribute preclinical research activity expense vary period number reason include time upfront milestone licensing payment increase attribute higher upfront milestone licensing payment unfavorable foreign exchange additional development cost result acquisition zymogenetic upfront milestone licensing payment million include million payment associate amendment intellectual property license agreement yervoy prior fda approval payment abbott laboratories abbott innate ambrx alder biopharmaceuticals inc alder nissan chemical industries ltd teijin pharma limited nissan teijin exclusive license develop commercialize certain program compound decrease attribute lower upfront milestone licensing payment partially offset additional spending support mature pipeline compound obtain stringofpearl strategy upfront milestone licensing payment million primarily attribute exelixis allergan inc abbott million primarily attribute zymogenetic alder nissan teijin provision restructuring provision restructure primarily attributable employee termination benefit continuous improvement initiative litigation expense net primarily million security litigation settlement equity net income affiliate equity net income affiliate primarily related international partnership sanofi vary base international plavix net sale include partnership decrease attribute impact alternative salt form clopidogrel generic clopidogrel competition international plavix net sale commence additional information item financial statementsnote alliance collaboration incomeexpense incomeexpense include year end december dollar million interest expense interest income impairment loss sale manufacturing operation gain sale product line business asset income receive alliance partner pension curtailment settlement charge litigation chargesrecoverie product liability charge recovery incomeexpense impairment loss sale manufacturing operation primarily attribute disposal manufacturing operation latina italy gain sale product line businesse asset primarily relate sale mature brand include business indonesia australia income alliance partner include income earn sanofi partnership amortization certain upfront milestone licensing payment relate alliance pension curtailment settlement charge primarily attribute amendment eliminate credit future benefit relate service pension plan participant amendment result curtailment charge million million respectively remainder charge result lump sum payment certain plan exceed sum plan interest cost service cost result acceleration portion previously defer actuarial loss additional charge recognize future particularly pension plan low threshold result elimination service cost potentially high lump sum payment item financial statementsnote pension postretirement postemployment liability detail product liability charge additional reserve connection breast implant settlement program hormone replacement therapy product nongaap financial measure nongaap financial measure include nongaap earning relate eps information adjust exclude certain cost expense gain loss specify item significant andor unusual nature evaluate individual basis item exclude segment income similar charge gain item recognize prior period reasonably possible reoccur future period nongaap information intend portray result baseline performance include discovery development licensing manufacturing marketing distribution sale pharmaceutical product global basis enhance investor overall understanding past financial performance prospect future example nongaap earning ep information indication baseline performance item consider reflective ongoing result addition information primary indicator use basis evaluate performance allocate resource set incentive compensation target planning forecast future period information intend consider isolation substitute net earning dilute eps prepared accordance gaap specify item follow year end december dollar million share datum cost product sell process standardization implementation cost bms foundation funding initiative marketing sell administrative upfront milestone licensing payment iprd impairment research development provision restructure litigation expense recovery impairment loss sale manufacturing operation gain sale product line business asset pension curtailment settlement charge acquisition relate item litigation chargesrecoverie product liability chargesrecoverie loss sale investment debt repurchase upfront milestone licensing receipt incomeexpense decrease pretax income income tax item outof period tax adjustment specify tax benefitcharge income taxis decrease net earning specify item include cost product sell include accelerate depreciation asset impairment shutdown cost specify tax benefit relate release tax reserve specify prior period specify tax charge relate tax charge additional taxable income earning foreign subsidiary previously consider permanently reinveste offshore reconciliation gaap nongaap follow year end december dollar million share datum net earning attributable bmsgaap earning attributable unvested restricted share net earning attributable bms diluted eps calculationgaap net earning attributable bmsgaap specify item net earning attributable bmsnongaap earning attributable unvested restricted share net earning attributable bms diluted eps calculationnongaap average common share outstandingdilute diluted eps attributable bmsgaap dilute eps attributable specify item dilute eps attributable bmsnongaap income taxis effective income tax rate earning continue operation income taxis effective income tax rate low statutory rate decision indefinitely reinvest earning certain manufacturing operation ireland puerto rico favorable tax rate ireland puerto rico grant schedule expire prior fluctuation effective tax rate impact million tax charge earning mix high low tax jurisdiction contingent tax matter change prior period estimate finalize tax return detail discussion change effective tax rate item financial statement note income taxis future effective tax rate adversely affect research development tax credit extend discontinue operation december complete splitoff remain interest mead johnson mean exchange offer bms shareholder item financial statementsnote mead johnson nutrition company initial public offering splitoff noncontrolle interest noncontrolle interest primarily relate partnership sanofi territory cover america relate plavix net sale item financial statementsnote alliance collaboration increase noncontrolle interest correspond increase net sale plavix follow expect loss exclusivity plavix avaproavalide expect significant decrease net earning attributable noncontrolle interest net earning discontinue operation attributable noncontrolle interest primarily relate publicly own portion mead johnson prior complete divestiture splitoff summary noncontrolle interest follow year end december dollar million sanofi partnership noncontrolle interestpretax income taxis net earning continue operation attributable noncontrolle interestnet taxis net earning discontinue operation attributable noncontrolle interestnet taxis net earning attributable noncontrolle interestnet taxis financial position liquidity capital resource net cash position follow dollar million cash cash equivalent marketable securitiescurrent marketable securitiesnoncurrent total cash cash equivalent marketable security shortterm borrowing include current portion longterm debt longterm debt net cash position maintain significant level work capital approximately billion december billion december future period expect cash generate operation exist cash cash equivalent marketable security borrowing capital market sufficient cover cash need dividend common stock repurchase debt repurchase strategic alliance acquisition include acquisition inhibitex billion milestone payment work capital capital expenditure rely shortterm borrowing meet current liquidity need cash cash equivalent marketable security hold billion december approximately billion remain billion hold low tax jurisdiction attributable earning expect indefinitely reinveste offshore cash repatriation subject restriction certain jurisdiction subject withholding taxis investment portfolio include noncurrent marketable security subject change fair value result interest rate fluctuation market factor impact result operation investment policy place limit investment time maturity investment institution policy require investment enter corporate financial institution meet high credit quality standard item financial statementsnote financial instrument discuss strategy loss exclusivity large product plavix expect result rapid precipitous material decline operate cash flow additional regulation pass future reduce result operation operate cash flow liquidity financial flexibility continue monitor potential impact economic condition certain european country relate impact prescription trend pricing discount creditworthiness customer ability collect outstanding receivable direct customer currently believe economic condition eu material impact liquidity cash flow financial flexibility mechanism limit overall credit exposure additional source liquidity sell trade receivable party principally wholesaler japan certain governmentbacked entity italy portugal spain sale trade receivable total approximately billion million million trade receivables sell italy portugal spain million million million available factored future ongoing european sovereign debt crisis sale agreement allow recourse event uncollectibility retain interest underlie asset sell september company replace billion revolve credit facility new billion year revolve credit facility syndicate lender contain customary term condition extendable anniversary date consent lender financial covenant new facility borrowing outstanding revolve credit facility december december continue manage operate cash flow initiative design improve work capital item directly affect change sale volume receivables inventory account payable follow summarize component express percentage trail month net sale trail trail december month december month dollar million net sale net sale net trade receivables inventory account payable total credit rating moodys investor service moodys longterm shortterm credit rating currently prime respectively longterm credit outlook remain stable standard poor sp longterm shortterm credit rating currently respectively longterm credit outlook remain stable fitch rating fitch longterm shortterm credit rating currently f respectively longterm credit outlook remain negative credit rating consider investment grade longterm rating designate low default risk somewhat susceptible adverse effect change circumstance economic condition shortterm rating designate strong capacity timely repayment cash flow follow discussion cash flow activity dollar million cash flow provide byused operating activity invest activity financing activity operate activity cash flow operating activity represent cash receipt cash disbursement activity invest activity financing activity operate cash flow derive adjust net earning noncontrolle interest noncash operating item gain loss attribute invest financing activity change operate asset liability result time difference receipt payment cash transaction recognize result operation result change cash operating activity reflect time cash collection customer alliance partner payment supplier alliance partner employee pension contribution tax payment ordinary course business operate cash flow continue benefit improve operating performance work capital initiative high unpaid rebate time increase lag payment manage care organization attribute government agency administrative delay invest activity net purchase marketable security million billion billion investment time deposit highly rate corporate debt security maturity great day increase manage return investment cash fund acquisition amira million include million contingent payment zymogenetic million medarex billion capital expenditure million million million include cost relate devens biologic facility cost support manufacturing initiative proceed million receive sale business asiapacific region mead johnson cash include splitoff transaction million financing activity dividend payment billion billion billion dividend declare common share december declare quarterly dividend common share expect pay dividend year share dividend decision quarterly basis board director billion stock repurchase program authorize result repurchase common stock billion million management periodically evaluate potential opportunity repurchase certain debt security terminate certain interest rate swap contract prior maturity cash outflow relate repurchase debt million million million proceed termination interest rate swap contract million million million proceed issuance common stock result stock option exercise million include million cash retain excess tax benefit million million issuance common stock result stock option exercise vary period base fluctuation market value stock relative exercise price stock option factor proceed billion receive mead johnson initial public offering issuance mead johnson note contractual obligation payment period contractual obligation december follow obligation expire period dollar million total later year shortterm borrowing longterm debt interest longterm debta operating lease purchase obligation uncertain tax positionsb longterm liability totalc include estimate future interest payment shortterm longterm debt security include accrue interest payable recognize consolidated balance sheet consist primarily accrue interest shortterm longterm debt accrue periodic cash settlement derivative b uncertainty relate timing reversal uncertain tax position shortterm uncertain tax benefit provide table item financial statementsnote income taxis detail c table exclude future contribution pension postretirement postemployment benefit plan require contribution contingent numerous factor include minimum regulatory funding requirement fund status plan uncertainty future obligation exclude table contribution international plan expect million item financial statementsnote pension postretirement postemployment liability detail addition commit billion aggregate potential future research development milestone payment party inlicense development program early stage milestone define milestone achieve phase iii clinical trial comprise billion total commit late stage milestone define milestone achieve post phase iii clinical trial comprise billion total commit payment agreement generally payable achievement certain developmental regulatory milestone specific timing predict addition certain royalty obligation calculate percentage net sale agreement provide salesbased milestone aggregate billion obligate pay alliance partner achievement certain sale level certain manufacturing development commercialization obligation connection alliance arrangement practicable estimate obligation item financial statementsnote alliance collaboration information alliance discussion contractual obligation item financial statementsnote pension postretirement postemployment liability note financial instrument note lease sec consent order previously disclose august enter final settlement sec concluding investigation concern certain wholesaler inventory accounting matter settlement reach consent copy attach exhibit quarterly report form q period end september term consent agree subject certain define exception limit sale product sell direct customer include wholesaler distributor hospital retail outlet pharmacie government purchaser base expect demand amount exceed approximately month inventory hand make timely public disclosure change practice agree consent certain measure implement include establish formal review certification process annual quarterly report file sec b establish business risk disclosure group c retain outside consultant comprehensively study help reengineer accounting financial reporting process publicly disclose sale incentive offer direct customer purpose induce purchase product excess expect demand e ensure budget process give appropriate weight input come adequately document process establish companywide policy limit sale direct customer purpose comply consent policy include adoption procedure monitor limit sale direct customer accordance term consent procedure include governance process escalate appropriate management level potential question concern compliance policy timely resolution question concern addition compliance policy monitor regular basis maintain inventory management agreement imas pharmaceutical wholesaler account nearly total gross sale biopharmaceutical product current term ima wholesaler customer provide weekly information respect month hand productlevel inventory outmovement product large wholesaler currently account approximately total gross sale biopharmaceutical product inventory information receive wholesaler internal information estimate month hand product level inventory wholesaler estimate month hand product inventory level biopharmaceutical businesss wholesaler customer large wholesaler extrapolate month hand calculate large wholesaler contrast biopharmaceutical business outside significantly direct customer limit information direct customer product level inventory correspond outmovement information reliability thirdparty demand information available vary widely accordingly rely variety method estimate month hand product level inventory business unit believe abovedescribe procedure provide reasonable basis ensure compliance consent recently issue accounting standard item financial statementsnote accounting policy discussion impact relate recently issue accounting standard critical accounting policy prepare financial statement conformity accounting principle generally accept preparation financial statement conformity generally accept accounting principle gaap require use estimate assumption affect report amount asset liability include disclosure contingent asset contingent liability date financial statement report amount revenue expense report period critical accounting policy important financial condition result operation require difficult subjective complex judgment management application result need estimate effect matter inherently uncertain new discount healthcare reform law medicare coverage gap manage medicaid require additional assumption lack historical claim experience increase lag claim datum addition new pharmaceutical company fee estimate subject external datum include company relative share industry result uncertainty factor surround estimate judgment preparation consolidated financial statement actual result vary estimate accounting policy discuss audit committee board director revenue recognition accounting policy revenue recognition substantial impact report result rely certain estimate recognize revenue persuasive evidence arrangement exist sale price fix determinable collectability reasonably assure title substantially risk reward ownership transfer generally time shipment net grosstonet sale adjustment discuss involve significant estimate judgment grosstonet sale adjustment follow category grosstonet sale adjustment involve significant estimate judgment require use information external source net sale discussion analysis significant category grosstonet sale adjustment chargeback related government program business participate program government entity significant department defense department veteran affair party include cover entity b drug pricing program pricing product extend wholesaler list price participate entity entity purchase product wholesaler low program price wholesaler charge difference acquisition cost low program price account chargeback reduce account receivable equal estimate chargeback claim attributable sale estimate chargeback primarily base historical experience program chargeback current contract price program consider chargeback payment level inventory distribution channel claim processing time lag adjust reserve reflect actual experience cash discount certain country offer cash discount incentive prompt payment generally approximate sale price account estimate cash discount reduce account receivable base historical claim experience adjust reserve reflect actual experience manage healthcare rebate contract discount offer rebate discount manage healthcare organization manage prescription drug program medicare advantage prescription drug plan cover medicare drug benefit addition commercial plan globally contract counterpartie hospital group purchasing organization begin rebate medicare program include discount company brandname drug patient fall medicare coverage gap addition accrue rebate department defense tricare retail pharmacy refund program account rebate discount establish accrual primarily base historical experience current contract price consider sale performance product subject rebate discount increase level unbilled claim level inventory distribution channel adjust accrual reflect actual experience medicaid rebate business participate state government medicaid program certain qualify federal state government program discount rebate provide participate state local government entity discount rebate provide program include medicaid rebate accrual consider medicaid rebate purpose discussion retroactive january minimum rebate medicaid drug sale increase medicaid rebate extend drug manage medicaid plan begin march account medicaid rebate establish accrual primarily base historical experience expansion prospective basis participation program legal interpretation applicable law new information change medicaid program regulation guideline impact rebate consider outstanding medicaid claim increase unbilled manage medicaid claim level inventory distribution channel adjust accrual reflect actual experience sale return account sale return establish accrual equal estimate sale recognize related product expect return primarily result product expiration return establish product determine estimate sale return accrual primarily base historical experience sale return consider factor impact sale return factor include level inventory distribution channel estimate shelf life product recall product discontinuance price change competitive product introduction generic product introduction competitive new product instance expect precipitous decline demand follow loss exclusivity consider factor adjust accrual reflect actual experience sale return accrual new product estimate primarily base historical sale return experience similar product line product similar therapeutic category limit circumstance new product extension exist line product historical experience product similar therapeutic category reliably estimate expect return new product defer recognition revenue right return long exist develop sufficient historical experience estimate sale return estimate level inventory distribution channel project demand consider new product yervoy net sale million defer patient infusion return policy establish quarter pharmaceutical company fee pharma fee begin pay annual nontaxdeductible fee federal government base allocation market share brand prior year sale certain government program include medicare medicaid department veterans affairs department defense tricare pharma fee finalize preliminary funding base information oneyear lag pharma fee calculate base market datum company industry participant company visibility fee classify financial reporting purpose operate expense use information external source use information external source estimate grosstonet sale adjustment estimate inventory wholesaler base project prescription demandbase sale product historical inventory experience analysis thirdparty information include write oral information obtain certain wholesaler respect inventory level sellthrough customer thirdparty market research datum internal information inventory information receive wholesaler product recordkeeping process exclude inventory hold intermediary sell retailer hospital continue practice combine retail mail prescription volume retailequivalent basis use methodology internal demand forecast use information external source identify prescription trend patient demand average selling price estimate subject inherent limitation estimate rely thirdparty information certain thirdparty information form estimate reflect limitation include lags date thirdparty information generate date receive thirdparty information retirement benefit pension postretirement benefit plan account actuarial valuation include key assumption discount rate expect longterm rate return plan asset consultation actuary key assumption salary growth retirement turnover healthcare trend mortality rate evaluate select base expectation actual experience remeasurement date pension expense vary range outcome material effect report earning project benefit obligation future cash fund actual result give year differ estimate economic factor yield high quality corporate bond coincide cash flow plan estimate payout determine discount rate citigroup pension discount curve plan plan pension expense determine weightedaverage discount rate present value benefit obligation december plan determine discount rate discount rate determine plan pension expense reduce expense increase approximately million assumed discount rate determine project benefit obligation december reduce project benefit obligation increase approximately billion expect longterm rate return plan asset estimate consider expect return individual asset class input external advisor consider longterm historical return include actual performance compare benchmark similar investment plan pension expense determine expect longterm rate return plan asset expect longterm rate return plan asset determine plan pension expense reduce expense increase million detailed discussion retirement benefit item financial statementsnote pension postretirement postemployment liabilitie business combination asset acquire liability assume recognize date acquisition respective fair value excess purchase price estimate fair value net asset acquire recognize goodwill determine fair value intangible asset include iprd typically use income method method start forecast expect future net cash flow risk adjust base estimate probability technical regulatory success adjust present value apply appropriate discount rate reflect risk associate cash flow stream asset value market participant view follow approach utilize specific intangible asset acquire iprd value preexist relationship acquiree consider term respective collaboration arrangement include cost profit sharing split project unit account typically global view consider potential jurisdiction indication technology relate specific platform value base expect annual number antibodie achieve early candidate nomination status technology commercial product value utilize multiperiod excessearning method income approach premise value intangible asset equal present value aftertax cash flow solely attribute intangible asset license value utilize discount cash flow method base estimate future riskadjuste milestone royalty payment project earn respective product estimate economic term significant estimate assumption include estimate project cash flow cash flow projection represent realizable market participant purchaser iprd assume initial positive cash flow commence shortly receipt expect regulatory approval typically occur number year actual cash flow attribute project likely different assume projection subject multiple factor include trial result regulatory matter materially change respective iprd ultimate commercial success significantly alter cost develop respective iprd commercially viable product probability regulatory success ptrs rate ptrs rate base industry average consider respective iprd development stage seek disease indication adjust specific information datum know iprd time acquisition subsequent clinical result internal external datum obtain alter ptrs rate materially impact intangible value discount rate select discount rate measure risk inherent future cash flow assessment asset life cycle competitive trend impact asset include consideration technical legal regulatory economic barrier entry expect change standard practice indication address asset useful life determine useful life intangible asset base period expect contribute future cash flow pertinent matter associate asset environment operate consider include legal regulatory contractual provision effect obsolescence demand competition economic factor item financial statementsnote acquisition specific detail value assign asset acquire liability assume acquisition amira september zymogenetics october medarex september significant estimate utilize time valuation support fair value lead compound acquisition include phase year discount development ptrs rate project positive dollar million fair value rate utilize acquisition date utilize cash flow amira phase ii zymogenetics pegylatedinterferon lambda phase iib medarex yervoy phase iii impairment goodwill goodwill tested annually impairment twostep process step identify potential impairment second step measure impairment loss goodwill consider impaired carrying reporting unit goodwill exceed estimate fair value geographical reporting unit aggregate impairment testing purpose base recent annual impairment test complete quarter fair value goodwill substantially excess relate carrying value discussion goodwill acquire inprocess research development intangible asset item financial statementsnote accounting policiesgoodwill acquire inprocess research development intangible asset indefinitelive intangible asset include iprd indefinitelive intangible asset subject amortization test impairment annually frequently event change circumstance indicate asset impair consider factor include stage development current legal regulatory environment competitive landscape adverse trial result significant delay obtain marketing approval inability bring respective product market result related intangible asset partially fully impair commercialize product inability meet sale forecast result related intangible asset partially fully impair consider industry success rate bring developmental compound market iprd impairment charge occur future period recognize charge million million relate medarex project development cease contingency normal course business subject contingency legal proceeding claim arise business cover wide range matter include government investigation shareholder lawsuit product environmental liability contractual claim tax matter recognize accrual contingency probable liability incur loss reasonably estimate estimate subject uncertainty difficult predict actual result vary estimate discussion contingency item financial statementsnote accounting policiescontingencie note income taxis note legal proceeding contingency income taxis valuation allowance recognize reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative judgment subject change adjustment defer tax valuation allowance earning period assessment defer tax asset billion net valuation allowance billion december billion net valuation allowance billion december recognize defer tax asset december relate federal net operating loss carryforward million federal research development tax credit carryforward million net operating loss carryforward expire vary amount begin research development tax credit carryforward expire vary amount begin realization carryforward dependent generating sufficient domesticsource taxable income prior expiration realization assure believe likely defer tax asset realize provide taxis undistribute earning foreign subsidiary expect reinveste indefinitely offshore company complete internal reorganization certain legal entity contribute million tax charge recognize fourth quarter possible tax authority assert additional material tax liability arise reorganization assertion occur company vigorously challenge assertion believe prevail assurance result prior mead johnson splitoff follow transaction occur internal spinoff mead johnson share own ii conversion mead johnson class b share class share iii conversion mead johnson company limited liability company transaction splitoff mead johnson exchange offer qualify taxexempt transaction internal revenue code base private letter ruling receive internal revenue service relate conversion mead johnson class b share class share outside legal opinion rely certain assumption representation covenant mead johnson future conduct business matter effect tax treatment exchange example current tax law generally create presumption exchange taxable mead johnson shareholders engage transaction result great change stock ownership year period begin year exchange offer establish exchange offer plan series relate transaction effect change ownership internal spinoff exchange offer determine qualify tax exempt transaction subject tax exchange taxable sale market value addition negative basis excess loss account ela investment stock mead johnson prior transaction receive opinion outside legal counsel effect likely eliminate ela transaction taxable income respect ela tax law area complex possible internal spinoff exchange offer tax exempt internal revenue code irs assert additional taxable income period respect ela expose additional taxis occur base understand internal revenue code opinion outside legal counsel tax reserve million establish reduce gain disposal mead johnson include discontinued operation agree certain tax relate indemnity mead johnson set forth tax sharing agreement example mead johnson agree indemnify potential tax effect result breach certain representation discuss certain transaction relate acquisition mead johnson stock asset agree indemnify mead johnson certain taxis relate business prior completion ipo create restructure facilitate ipo establish liability possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense liability represent reasonable provision taxis ultimately expect pay need adjusted time information know discussion income taxis item financial statementsnote accounting policiesincome taxis note income taxis special note forwardlooke statement annual report include document incorporate reference write oral statement time time contain certain forwardlooking statement meaning section security act section e securities exchange act identify forwardlooke statement fact use word expect anticipate estimate target project guidance intend plan believe word term similar meaning expression connection discussion future operate financial performance identify forwardlooke statement fact relate strictly historical current fact forwardlooke statement base current expectation involve inherent risk uncertainty include factor delay divert change cause actual outcome differ materially current expectation statement likely relate thing goal plan projection financial position result operation cash flow market position product development product approval sale effort expense performance result current anticipate product outcome contingency legal proceeding financial result base current expectation involve inherent risk uncertainty include internal external factor delay divert change year include important factor cautionary statement include annual report particularly item risk factor believe cause actual result differ materially forwardlooke statement believe prudent plan assumption assurance give goal plan set forth forwardlooke statement achieve reader caution place undue reliance statement speak date undertake obligation release publicly revision forwardlooke statement result new information future event item quantitative qualitative disclosure market risk expose market risk change currency exchange rate interest rate result certain derivative financial instrument available costeffective basis hedge underlie economic exposure financial instrument include derivative subject counterparty credit risk consider overall fair value measurement derivative financial instrument trading purpose foreign exchange risk significant portion revenue earning cash flow expose change foreign currency rate primary net foreign currency translation exposure euro japanese yen canadian dollar chinese renminbi australian dollar foreign currency forward contract manage foreign exchange risk primarily arise certain intercompany purchase transaction designate derivative instrument foreign currency cash flow hedge appropriate addition expose foreign exchange transaction risk arise nonfunctional currency denominate asset liability earning denominate nonus dollar currency foreign currency forward contract offset portion exposure designate hedge change fair value derivative recognize earning incur estimate appreciation underlie currency hedge level dollar december variable hold constant decrease fair value foreign exchange forward contract hold december million realize negatively affect earning remain life contract expose translation risk nonus dollardenominate net asset nonus dollar borrowing hedge foreign currency exposure net investment certain foreign affiliate designate hedge net investment effective portion foreign exchange gain loss hedge recognize foreign currency translation component accumulate oci net investment fall equivalent value euro debt borrowing change remeasurement basis debt subject recognition income change occur additional information item financial statementsnote financial instrument interest rate risk fixedtofloate interest rate swap designate fairvalue hedge interest rate risk management strategy swap intend provide appropriate balance fix float rate debt estimate increase basis point shortterm longterm interest rate decrease fair value interest rate swap million exclude effect counterparty credit risk realize affect earning remain life swap marketable security subject change fair value result interest rate fluctuation market factor policy inv institution meet high credit quality standard estimate increase basis point interest rate general decrease fair value debt security portfolio approximately million credit risk exposure european sovereignbacke trade receivables material continue limit credit exposure certain country significantly impact sovereign debt crisis europe identify governmentbacke entity high risk default monitor social economic factor include credit rating creditdefault swap rate debttogross domestic product ratio material provide additional bad debt reserve italy greece portugal spain defer immaterial revenue certain governmentbacked entity greece portugal spain collection reasonably assure periodically sell certain nonus trade receivables mean reduce collectability risk sale agreement provide recourse event uncollectibility retain interest underlie asset sell volume trade receivables sell italy portugal spain sustainable future year ongoing european sovereign debt crisis monitor investment counterpartie objective minimize concentration credit risk investment policy place limit time maturity investment individual counterparty policy require investment primarily highly rate corporate financial government government support institution use derivative instrument expose credit risk fair value derivative instrument contract positive expose credit risk counterparty fails perform fair value derivative instrument contract negative counterparty expose credit risk fail perform obligation term agreement post collateral require party derivative asset liability position policy diversify derivative counterpartie mitigate overall risk counterparty default additional information item financial statement note financial instrument bristolmyers squibb company consolidate statement earning dollar share million share datum item financial statement supplementary datum year end december earning net sale cost product sell marketing sell administrative advertising product promotion research development provision restructure litigation expense net equity net income affiliate incomeexpense total expense earning continue operation income taxis provision income taxis net earning continue operation discontinue operation earning net taxis gain disposal net taxis net earning discontinue operation net earning net earning attributable noncontrolle interest net earning attributable bristolmyer squibb company amount attributable bristolmyer squibb company net earning continue operation net earning discontinue operation net earning attributable bristolmyer squibb company earning common share continue operation attributable bristolmyer squibb company basic diluted earning common share attributable bristolmyer squibb company basic dilute dividend declare common share accompany note integral consolidated financial statement bristolmyers squibb company consolidate statement comprehensive income dollar millions year end december comprehensive income net earning comprehensive incomeloss foreign currency translation foreign currency translation reclassify net earning business divestiture foreign currency translation net investment hedge derivative qualify cash flow hedge net taxis derivative qualify cash flow hedge reclassify net earning net taxis derivative reclassify net earning business divestiture net taxis pension postretirement benefit net taxis pension postretirement benefit reclassify net earning net taxis pension postretirement benefit reclassify net earning business divestiture net taxis available sale security net taxis available sale security reclassify net earning net taxis total comprehensive incomeloss comprehensive income comprehensive income attributable noncontrolle interest comprehensive income attributable bristolmyer squibb company accompany note integral consolidated financial statement bristolmyers squibb company consolidated balance sheet dollar million share share datum december asset current asset cash cash equivalent marketable security receivables inventory defer income taxis prepaid expense total current asset property plant equipment goodwill intangible asset defer income taxis marketable security asset total asset liability current liability shortterm borrowing account payable accrue expense defer income accrue rebate return foreign income taxis payable dividend payable total current liability pension postretirement postemployment liability defer income foreign income taxis payable liability longterm debt total liability commitment contingency note equity bristolmyers squibb company shareholder equity prefer stock convertible series par value share authorize million share issue outstanding liquidation value share common stock par value share authorize billion share billion issue capital excess par value stock accumulate comprehensive loss retain earning cost treasury stock million common share million total bristolmyer squibb company shareholder equity noncontrolle interest total equity total liability equity accompany note integral consolidated financial statement bristolmyers squibb company consolidate statement cash flow dollar million year end december cash flow operating activity net earning adjustment reconcile net earning net cash provide operating activity net earning attributable noncontrolle interest depreciation amortization defer income tax expense stockbase compensation expense impairment charge gain related divestiture discontinue operation adjustment change operate asset liability receivable inventory account payable deferred income foreign income taxis payable net cash provide operating activity cash flow invest activity proceed sale maturity marketable security purchase marketable security addition property plant equipment capitalize software proceed sale business invest activity mead johnson cash splitoff purchase business net cash acquire net cash investing activity cash flow financing activity shortterm debt repayment longterm debt borrowing longterm debt repayment interest rate swap termination issuance common stock common stock repurchase dividend pay proceed mead johnson initial public offer net cash financing activity effect exchange rate cash cash equivalent increasedecrease cash cash equivalent cash cash equivalent begin year cash cash equivalent end year accompany note integral consolidated financial statement note accounting policy basis consolidation consolidate financial statement prepare conformity united states generally accept accounting principle gaap include account bristolmyer squibb company refer bristolmyer squibb bms company control majorityowned subsidiary intercompany balance transaction eliminate material subsequent event evaluate disclose report issuance date codevelopment cocommercialization license arrangement enter party therapeutic area term include upfront licensing contingent payment arrangement assess determine term economic control entity require consolidation entity entity consolidated control mean majority voting interest refer variable interest entity arrangement material variable interest entity include associated codevelopment cocommercialization license arrangement determine exist use estimate preparation financial statement require use management estimate assumption base complex judgment significant assumption employ estimate determine fair value intangible asset restructuring charge accrual sale rebate return accrual include relate healthcare reform legal contingency tax asset tax liability stockbase compensation expense pension postretirement benefit include actuarial assumption note pension postretirement postemployment liability fair value financial instrument direct observable market quote inventory obsolescence potential impairment longlive asset allowance bad debt estimate apply revenue recognition policy new discount healthcare reform law medicare coverage gap manage medicaid require additional assumption lack historical claim experience addition new pharmaceutical company fee estimate subject external datum calculation base company relative share industry result actual result differ estimate result revenue recognition revenue recognize persuasive evidence arrangement exist sale price fix determinable collectability reasonably assure title substantially risk reward ownership transfer generally time shipment certain sale nonus business recognize date receipt purchaser note alliance collaboration discussion revenue recognition relate alliance provision time revenue recognition expect sale return discount rebate estimate sale allowance base historical experience update change fact circumstance include impact new legislation provision recognize reduction revenue limit circumstance new product extension exist line product historical experience product similar therapeutic category exist revenue defer right return long exist sufficient historical experience estimate sale return develop income taxis provision income taxis determine asset liability approach accounting income taxis approach defer taxis represent future tax consequence expect occur report amount asset liability recover pay provision income taxis represent income taxis pay payable current year plus change defer taxis year defer taxis result difference financial tax basis asset liability adjust change tax rate tax law change enact valuation allowance recognize reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning period assessment cash cash equivalent cash cash equivalent consist treasury security government agency security bank deposit time deposit money market fund cash equivalent consist highly liquid investment original maturity month time purchase recognize cost approximate fair value marketable security investment company marketable security classify availableforsale date purchase report fair value december fair value determine base observable market quote valuation model assessment counterparty credit worthiness credit default risk underlie security overall capital market liquidity decline fair value consider temporary charge earning consider temporary report component accumulate comprehensive income oci shareholder equity decline fair value determine credit relate charge earning average cost method determine realize gain loss sale availableforsale security investment own company ability exercise significant influence maintain account equity method accounting share net income loss equity investment include equity net income affiliate consolidated statement earning equity investment review impairment assess decline market value investment carry value temporary consider intent ability retain investment length time extent market value cost financial condition investee inventory valuation inventory state low average cost market property plant equipment depreciation expenditure addition renewal improvement capitalize cost depreciation compute straightline method base estimate useful life relate asset estimate useful life depreciable asset range year building year machinery equipment fixture impairment longlive asset current fact circumstance periodically evaluate determine carry value depreciable asset hold recoverable circumstance exist estimate undiscounted future cash flow generate longlived asset appropriate grouping asset compare carry value determine impairment exist low level identifiable cash flow asset determine impair loss measure base difference asset fair value carry value estimate asset fair value base quote market price active market available quote market price available estimate fair value base valuation technique include discount value estimate future cash flow longlived asset hold sale report low carrying value estimate net realizable value capitalize software certain cost obtain internal use software significant system project capitalize amortize estimate useful life software cost obtain software project significant expense incur business combination business acquire include consolidated financial statement obtain control acquiree asset acquire liability assume recognize date acquisition respective fair value excess purchase price estimate fair value net asset acquire recognize goodwill legal cost audit fee business valuation cost business acquisition cost expense incur goodwill acquire inprocess research development intangible asset goodwill test impairment annually twostep process step identify potential impairment second step measure impairment loss goodwill impaired carrying reporting unit goodwill exceed estimate fair value geographical reporting unit aggregate impairment testing purpose annual goodwill impairment assessment complete quarter subsequently monitor potential impairment remain quarter indicate impairment goodwill fair value inprocess research development iprd acquire business combination determine base present value research project project cash flow income approach future cash flow predominately base net income forecast project consistent historical pricing margin expense level similar product revenue estimate base relevant market size growth factor expect industry trend individual project life cycle life research project underlie patent determine fair value research project expect revenue adjust probability regulatory success result cash flow discount rate approximating company weightedaverage cost capital iprd initially capitalize consider indefinitelived asset subject annual impairment review occurrence certain event review require determination fair value respective intangible asset fair value intangible asset carry value impairment loss recognize difference compound reach commercialization asset amortize expect useful life patentstrademark license technology amortize straightline basis estimate useful life monitor impairment trigger consider impair net carry value exceed estimate fair value restructure restructuring charge recognize result action streamline operation rationalize manufacture facility judgment estimate impact restructuring plan include future termination benefit exit cost incur action place actual result vary estimate contingency loss contingency legal proceeding claim occur wide range matter include government investigation shareholder lawsuit product environmental liability contractual claim tax matter accrual recognize probable liability incur loss reasonably estimate gain contingency recognize realize legal fee expense incur derivative financial instrument derivative financial instrument principally management interest rate foreign currency exposure hold issue trading purpose derivative instrument recognize fair value change derivative fair value recognize earning specific hedge criterion meet derivative designate fair value hedge change fair value derivative hedge item attributable hedge risk recognize earning derivative designate cash flow hedge effective portion change fair value derivative report accumulate comprehensive income oci subsequently recognize earning hedge item affect earning cash flow classify consistent underlying hedged item derivative designate assign hedge forecast transaction specific asset specific liability hedge asset liability sell extinguish forecast transaction hedge long probable occur gain loss immediately recognize designate hedge earning nonderivative instrument designate hedge net investment foreign affiliate nonderivative instrument mainly euro denominate longterm debt effective portion designate nonderivative instrument recognize foreign currency translation section oci ineffective portion recognize earning shipping handle cost shipping handling cost include marketing sell administrative expense million million million million include discontinue operation advertising product promotion cost advertising product promotion cost expense incur foreign currency translation foreign subsidiary earning translate dollar average exchange rate net asset foreign subsidiary translate dollar current exchange rate dollar effect arise translate net asset subsidiary change rate recognize oci net asset subsidiary highly inflationary economy remeasure functional currency report currency remeasurement recognize earning research development research development cost expense incur clinical study cost accrue service period specify contract adjust necessary base ongoing review level effort cost actually incur strategic alliance party provide right develop manufacture market andor sell pharmaceutical product right own party certain research development payment alliance partner contingent achievement certain predetermine criterion milestone payment achieve prior regulatory approval product expense research development milestone payment connection regulatory approval capitalize amortize cost product sell remain useful life asset capitalize milestone payment test recoverability periodically event change circumstance indicate carrying amount recoverable research development recognize net reimbursement connection collaboration agreement upfront license milestone receipt obtain development defer amortize estimate life product income company future obligation development upfront license milestone receipt recognize immediately income amortization period upfront license milestone receipt new materially modify arrangement january assess determine consider term arrangement recently issue accounting standard january new revenue recognition standard adopt new materially modify revenue arrangement upfront licensing fee contingent milestone relate research development deliverable guidance provide principle application guidance multiple deliverable exist arrangement separate consideration allocate adoption standard impact consolidate financial statement september fasb amend guidance goodwill impairment testing amendment allow entity assess qualitative factor determine fair value report unit exceed carry value entity conclude qualitative assessment likely fair value report unit exceed carry value perform twostep impairment test unnecessary standard effective fiscal year begin december expect impact consolidate financial statement note business segment information bms operate single segment engage discovery development licensing manufacturing marketing distribution sale innovative medicine help patient prevail disease global research development organization global supply chain organization utilize responsible development delivery product market product distribute sell regional organization serve united states europe latin america middle east africa japan asia pacific canada emerge market define brazil russia india china turkey business support global corporate staff function segment information present consistent financial information regularly review chief operating decision maker chief executive officer purpose evaluate performance allocate resource set incentive compensation target planning forecast future period product sell principally wholesaler less extent directly distributor retailer hospital clinic government agency pharmacie gross sale large pharmaceutical wholesaler percentage total gross sale follow mckesson corporation cardinal health inc amerisourcebergen corporation select geographic area information follow property plant net sale equipment dollar millions united states europe japan asia pacific canada latin america middle east africa emerge market total net sale key product follow year end december dollar millions plavix clopidogrel bisulfate avaproavalide irbesartanirbesartanhydrochlorothiazide abilify aripiprazole reyataz atazanavir sulfate sustiva efavirenz franchise baraclude entecavir erbitux cetuximab sprycel dasatinib yervoy ipilimumab orencia abatacept nulojix belatacept onglyzakombiglyze saxagliptinsaxagliptin metformin mature product net sale capital expenditure depreciation property plant equipment segment follow year end december dollar million capital expenditure depreciation segment income exclude impact significant item indicative current operating performance ongoing result earning attribute sanofi noncontrolle interest reconciliation earning continue operation income taxis follow year end december dollar million segment income reconcile item provision restructuring impairment loss sale manufacturing operation accelerate depreciation asset impairment shutdown cost process standardization implementation cost gain sale product line business asset litigation recoverycharge upfront milestone licensing payment bms foundation funding initiative noncontrolle interest earning continue operation income taxis note alliance collaboration sanofi bms agreement sanofi codevelopment cocommercialization avaproavalide angiotensin ii receptor antagonist indicate treatment hypertension diabetic nephropathy plavix platelet aggregation inhibitor worldwide alliance operate framework geographic territory america principally canada puerto rico latin american countries australia europe asia accordingly territory partnership form manage central expense market research development royalty supply finish product individual country general country level agreement copromote partnership form party sell brand comarket party operate sell brand independently place agreement expire expiration patent exclusivity right applicable territory bms act operating partner own majority control interest territory cover americas australia consolidate country partnership result territory sanofis share result reflect noncontrolle interest bms recognize net sale territory comarkete country outside territory eg germany italy irbesartan spain greece royalty owe sanofi include cost product sell development royalty sanofi act operating partner own majority control interest territory cover europe asia bms ownership interest territory account equity method distribution profit relate partnership include operating activity bms sanofi separate partnership governing copromotion irbesartan bms recognize income relate amortization defer income associate sanofis million payment bms acquisition interest irbesartan license formation alliance certain supply activity development optout royalty sanofi reflect net basis incomeexpense fourth quarter bm establish million reserve relate avalide supply disruption early connection ongoing negotiation sanofi charge include expense summarize financial information relate alliance follow year end december dollar million territory cover americas australia net sale royalty expense noncontrolle interest pretax profit distribution sanofi territory cover europe asia equity net income affiliate profit distribution bms net sale europe comarkete country amortization incomeexpense irbesartan license fee supply activity development optout royalty incomeexpense december dollar million investment affiliate territory cover europe asia defer income irbesartan license fee follow summarize financial information interest partnership sanofi territory cover europe asia consolidated account equity method year end december dollar million net sale cost product sell gross profit marketing sell administrative advertising product promotion research development incomeexpense net income current asset current liability cost product sell include discovery royalty million million million pay directly sanofi expense share base applicable ownership percentage current asset current liability include approximately million million billion relate receivablespayable attribute respective year net cash distribution bms sanofi intercompany balance partnership territory remain current asset current liability consist thirdparty trade receivables inventory amount bms sanofi purchase inventory royaltie expense reimbursement otsuka bms worldwide commercialization agreement otsuka pharmaceutical co ltd otsuka codevelop copromote abilify treatment schizophrenia bipolar mania disorder major depressive disorder exclude certain asia pacific country portion amend commercialization manufacturing agreement expire expect loss product exclusivity april contractual share abilify net sale recognize bms begin january contractual share revenue recognize bms reduce uk germany france spain bms receive thirdparty net sale country thirdparty customer invoice bms behalf otsuka alliance revenue recognize abilify ship risk reward ownership transfer party customer certain country bms presently exclusive distributor product exclusive right sell abilify bms recognize net sale bms purchase product otsuka perform finish manufacture sale thirdparty customer bms otsuka term amend agreement bm pay otsuka million amortize reduction net sale expect loss exclusivity april unamortized balance include asset otsuka receive royalty base total net sale include cost product sell otsuka responsible expense relate commercialization abilify reimbursement net principally marketing sell administrative advertising product promotion expense begin january expect loss exclusivity april include expect month pediatric extension bms receive follow percentage annual net sale share net sale billion billion billion billion billion billion billion billion billion excess billion period otsuka responsible expense relate commercialization abilify bms otsuka enter oncology collaboration sprycel ixempra japan european union eu market oncology territory collaboration fee classify cost product sell pay otsuka base follow percentage annual net sale sprycel ixempra oncology territory net sale million million million million million million billion excess billion period otsuka contribute million certain commercial operational expense relate oncology product ii commercial operational expense relate product territory excess million begin otsuka copromote sprycel japan exercise right copromote eu market begin january extension oncology collaboration include changeofcontrol provision case acquisition bms acquire company compete product abilify new company assume abilify agreement amend oncology collaboration exist today acquire company product compete abilify otsuka elect request acquire company choose div abilify compete product scenario abilify divest otsuka obligate acquire right bms abilify agreement amend agreement provide event generic competitor abilify january bms option terminate abilify april amendment agreement previously amend remain force bms exercise option bms receive payment otsuka accord predetermine schedule oncology collaboration terminate time ii oncology collaboration continue truncated period accord predetermine schedule eu agreement remain unchanged expire june country bms exclusive right sell abilify agreement expire later th anniversary commercial sale country expiration applicable patent country addition million extension payment total milestone payment otsuka agreement december million million expensed iprd remain million capitalize intangible asset amortize cost product sell remain life original agreement summarize financial information relate alliance follow year end december dollar million abilify net sale include amortization extension payment oncology product collaboration fee expense royalty expense reimbursement operating expense tofrom otsuka amortization incomeexpense extension payment amortization incomeexpense upfront milestone licensing payment december dollar million asset extension payment intangible asset upfront milestone licensing payment january bm grant otsuka exclusive right develop commercialize onglyza japan bms expect receive milestone payment base certain regulatory event salesbase payment follow regulatory approval onglyza japan retain right copromote onglyza otsuka japan otsuka responsible development cost japan lilly bms epidermal growth factor receptor egfr commercialization agreement eli lilly company lilly lilly acquisition imclone system incorporate imclone codevelopment promotion erbitux necitumumab imcf expire erbitux september bms codevelopment copromotion right product canada japan erbitux indicate use treatment patient metastatic colorectal cancer use treatment squamous cell carcinoma head neck egfr agreement respect erbitux sale north america lilly receive distribution fee base flat rate net sale north america plus reimbursement certain royalty pay lilly include cost product sell bms imclone amend codevelopment agreement merck kgaa merck provide cocommercialization erbitux japan right agreement expire lilly ability terminate agreement determine commercially unreasonable lilly continue erbitux receive marketing approval japan use erbitux treat patient advance recurrent colorectal cancer bms receive pretax profit merck sale erbitux japan share equally lilly profit sharing commercialization japan attribute bms include income bms amortize million license acquisition cost bms lilly restructure egfr commercialization agreement describe bms imclone relate necitumumab novel target cancer therapy currently phase iii development nonsmall cell lung cancer restructure company share cost develop potentially commercialize necitumumab canada japan lilly maintain exclusive right necitumumab market bms fund development cost study japan studies fund global study bms pay million lilly milestone payment approval canada bms recognize sale profit loss necitumumab lilly provide selling effort party general equally participate commercialization effort japan bms lilly share commercial cost profit evenly agreement relate necitumumab continue patent expiration party agree terminate terminate time bms month advance notice month prior launch party uncured material breach party agree terminate lilly responsible manufacturing bulk requirement bms responsible fillfinish necitumumab summarize financial information relate alliance follow year end december dollar million net sale distribution fee royalty expense research development expense reimbursement lilly necitumumab amortization incomeexpense upfront milestone licensing payment japan commercialization fee incomeexpense december dollar million intangible asset upfront milestone licensing payment gilead bms gilead sciences inc gilead joint venture develop commercialize atripla efavirenz mg emtricitabine mg tenofovir disoproxil fumarate mg oncedaily single tablet threedrug regimen treatment human immunodeficiency virus hiv infection combine sustiva product bms truvada emtricitabine tenofovir disoproxil fumarate product gilead canada europe bms account participation joint venture equity method account net sale bulk efavirenz component atripla defer combined product sell thirdparty customer net sale efavirenz component base relative ratio average respective net selling price truvada sustiva summarize financial information relate alliance follow year end december dollar million net sale equity net loss affiliate astrazeneca bms maintain worldwide codevelopment cocommercialization agreement astrazeneca plc astrazeneca onglyzakombiglyze exclude japan dapagliflozin onglyza kombiglyze indicate use treatment diabetes dapagliflozin currently study treatment diabetes onglyza dapagliflozin discover bms kombiglyze codevelope astrazeneca company jointly develop clinical marketing strategy share commercialization expense profit loss equally global basis share development cost bms manufacture product bms option decline involvement cocommercialization give country instead receive tiere royalty base net sale reimbursement development commercial cost sharing include research development advertising product promotion marketing sell administrative expense expense attributable astrazeneca share profit include cost product sell bms receive million upfront milestone licensing payment relate saxagliptin december receive additional million salesbased milestone bms receive million upfront milestone licensing payment relate dapagliflozin december potentially receive additional million development regulatory milestone additional million salesbased milestone upfront milestone licensing payment defer amortize estimate useful life product income summarize financial information relate alliance follow year end december dollar million net sale profit share expense commercialization expense reimbursement tofrom astrazeneca research development expense reimbursement tofrom astrazeneca amortization incomeexpense upfront milestone licensing payment upfront milestone licensing payment receive saxagliptin dapagliflozin december dollar millions deferred income upfront milestone licensing payment saxagliptin dapagliflozin pfizer bms pfizer inc pfizer maintain worldwide codevelopment cocommercialization agreement eliquis anticoagulant discover bms prevention treatment atrial fibrillation arterial thrombotic condition pfizer fund development cost initial development plan effective january company jointly develop clinical marketing strategy share commercialization expense profit equally global basis bms manufacture product reimbursement development cost commercial cost sharing include research development advertising product promotion marketing sell administrative expense bms receive million upfront milestone licensing payment eliquis date include million receive january receive additional million development regulatory milestone payment defer amortized estimate useful life product income summarize financial information relate alliance follow year end december dollar million commercialization expense reimbursement tofrom pfizer research development reimbursement tofrom pfizer amortization incomeexpense upfront milestone licensing payment upfront milestone licensing payment receive december dollar millions deferred income upfront milestone licensing payment note acquisition amira pharmaceuticals inc september bms acquire outstanding share amira pharmaceuticals inc amira million cash plus separate contingent million payment achievement certain development salesbase milestone contingent payment fourth quarter fair value total contingent consideration million record liability acquisition cost million include expense amira privatelyheld biotechnology company primarily focus discovery development therapeutic product treatment cardiovascular fibrotic inflammatory disease acquisition provide bms right develop commercialize complete phase clinical study remainder amira lysophosphatidic acid receptor antagonist program researcher fibrotic expertise preclinical autotaxin program goodwill generate acquisition primarily attribute acquire scientific expertise fibrotic disease allow expansion new therapeutic class contingent liability estimate utilize model assess probability achieve milestone discount potential payment base expect timing estimate evaluate contingent liability consistent evaluate acquire iprd discount rate payment consistent market debt yield noncallable publiclytraded bond bms similar maturity estimate potential payment date fair value measurement base significant input observable market represent level measurement result amira operation include consolidated financial statement september zymogenetics inc acquisition october bms acquire outstanding share common stock zymogenetics inc zymogenetics october aggregate purchase price approximately million acquisition cost million include expense zymogenetic focus develop commercialize therapeutic proteinbase product treatment human disease company collaborate development pegylatedinterferon lambda novel interferon phase iib development acquisition date treatment hepatitis c infection acquisition provide company right develop commercialize pegylatedinterferon lambda value million iprd acquisition date bring prove capability therapeutic protein revenue recothrom fda approve specialty surgical biologic goodwill generate acquisition primarily attribute ownership right pegylatedinterferon lambda result zymogenetic operation include consolidated financial statement october medarex inc acquisition september bms acquire mean tender offer secondstep merger remain outstanding share stock equivalent medarex own total purchase price million acquisition cost million include expense medarex focus discovery development commercialization fully human antibodybased therapeutic product address major unmet healthcare need area oncology inflammation autoimmune disorder infectious disease result acquisition right yervoy ipilimumab value billion acquisition date receive increase biologics development pipeline create balanced portfolio small molecule biologic goodwill generate acquisition primarily attribute balanced portfolio associated biopharma model potential optimize exist yervoy program result medarex operation include consolidated financial statement august purchase price allocation follow dollar millions amira zymogenetics medarex purchase price cash fair value contingent consideration fair value company equity hold prior acquisition total identifiable net asset cash marketable security inventory current longterm asset iprd intangible asset technology intangible asset license shortterm borrowing accrue expense current longterm liability defer income taxis total identifiable net asset goodwill income million recognize remeasurement fair value equity interest medarex hold acquisition date inventory relate zymogenetic acquisition include million record long term asset inventory expect utilize excess year current long term asset relate medarex acquisition include ownership interest genmab inc million ownership celldex therapeutic inc million subsequently sell loss million pro forma supplemental financial information provide impact acquisition material operating result year acquisition goodwill iprd intangible asset value acquisition nondeductible tax purpose note mead johnson nutrition company initial public offering splitoff mead johnson nutrition company initial public offering february mead johnson nutrition company mead johnson complete initial public offering ipo sell million share class common stock share net proceed million deduct million underwriting discount commission offer expense allocate noncontrolle interest capital excess par value stock completion ipo million share mead johnson class common stock million share mead johnson class b common stock hold bms represent interest mead johnson combine voting power outstanding common stock right holder share class common stock class b common stock identical regard voting conversion share class common stock entitle vote share share class b common stock entitle vote share convertible time election holder share class common stock class b common stock automatically convert share class common stock agreement relate separation mead johnson enter include separation agreement transitional service agreement tax matter agreement registration right agreement employee matter agreement mead johnson nutrition company splitoff splitoff remain interest mead johnson complete december splitoff effect exchange offer previously hold million share mead johnson converting class b common stock class common stock million outstanding share company stock result pretax gain million million net taxis share receive connection exchange value closing price december reflect treasury stock gain exchange determine sum fair value share receive plus net deficit mead johnson attributable bms taxis direct expense relate transaction include tax reserve million establish transitional relationship discontinue operation subsequent respective disposition cash flow income associate mead johnson business continue generate september relate activity transitional nature result agreement intend facilitate orderly transfer business operation include service accounting customer service distribution manufacturing income generate transitional activity substantially complete december material period present follow summarize financial information relate mead johnson business segregate continue operation report discontinue operation date disposition year end december dollar million net sale earning income taxis provision income taxis earning net taxis gain disposal provision income taxis gain disposal net taxis net earning discontinue operation net earning discontinue operation attributable noncontrolle interest net earning discontinue operation attributable bms note restructuring follow provision restructuring year end december dollar million employee termination benefit exit cost provision restructure restructuring charge include termination benefit workforce reduction manufacturing sell administrative research development personnel geographic region approximately follow table represent activity employee termination exit cost liability year end december dollar million liability begin year charge change estimate provision restructure foreign currency translation charge discontinue operation spend mead johnson splitoff liability end year note incomeexpense incomeexpense include year end december dollar million interest expense interest income impairment loss sale manufacturing operation gain sale product line business asset income receive alliance partner pension curtailment settlement charge litigation chargesrecoverie product liability chargesrecoverie incomeexpense note income taxis provisionbenefit income taxis attributable continue operation consist year end december dollar millions current nonus total current defer nonus total defer total provision effective tax rate reconciliation effective tax rate statutory federal income tax rate earning income taxis dollar million earning continue operation income taxis nonus total statutory rate nontax deductible annual pharmaceutical company fee tax effect foreign subsidiary earning previously consider indefinitely reinveste offshore foreign tax effect certain operation ireland puerto rico switzerland state local taxis net valuation allowance federal state foreign contingent tax matter federal research development tax credit foreign decrease effective tax rate million charge recognize fourth quarter result primarily additional taxable income earning foreign subsidiary previously consider indefinitely reinveste offshore change prior period estimate finalize tax return result million benefit million charge high tax benefit contingent tax matter primarily relate effective settlement remeasurement uncertain tax position million million partially offset unfavorable earning mix high low tax jurisdiction compare prior year nontax deductible annual pharmaceutical company fee effective january tax impact million outofperiod tax adjustment million previously unrecognized net defer tax asset primarily attribute deferred profit relate certain alliance december material prior period increase effective tax rate million charge recognize fourth quarter discuss change prior period estimate finalize tax return result million charge million benefit finalize tax return unfavorable earning mix high low tax jurisdiction compare prior year partially offset high tax benefit contingent tax matter primarily relate effective settlement remeasurement uncertain tax position million million outofperiod tax adjustment million discuss defer taxis valuation allowance component current noncurrent defer income tax assetsliabilitie follow december dollar millions defer tax asset foreign net operating loss carryforward milestone payment license fee defer income federal net operating loss carryforward pension postretirement benefit state net operating loss credit carryforward intercompany profit inventory item federal research development tax credit carryforward foreign defer tax asset sharebase compensation legal settlement total defer tax asset valuation allowance net defer tax asset defer tax liability depreciation repatriation foreign earning acquire intangible asset total defer tax liability defer tax asset net recognize deferred income taxis current deferred income taxis noncurrent foreign income taxis payable current liability noncurrent total federal net operating loss carryforward million december carryforward acquire result certain acquisition subject limitation section internal revenue code net operating loss carryforward expire vary amount begin research development tax credit carryforward expire vary amount begin realization research development tax credit carryforward dependent generating sufficient domesticsource taxable income prior expiration realization assure management believe likely defer tax asset realize december valuation allowance million establish follow item million foreign net operating loss tax credit carryforward million state defer tax asset include net operating loss tax credit carryforward million federal net operating loss carryforward foreign hold company net operating loss correspond valuation allowance include increase million result statutory impairment charge require consolidated net earning foreign hold company high asset basis statutory purpose basis consolidated financial statement internal reorganization certain legal entity prior period change valuation allowance follow year end december dollar million balance begin year provision utilization foreign currency translation balance end year income tax payment million million million current tax benefit realize result stock relate compensation credit capital excess par value stock million million million december taxis provide approximately billion undistributed earning foreign subsidiary undistribute earning indefinitely invest offshore future earning repatriate earning determine remit foreseeable future additional tax provision require complexity tax law assumption practicable estimate amount income taxis provided bms favorable tax rate ireland puerto rico grant schedule expire prior bms complete internal reorganization certain legal entity result million charge possible tax authority assert additional material tax liability arise reorganization assertion occur bms vigorously challenge assertion believe prevail assurance result business conduct country world subject tax numerous jurisdiction result significant number tax return file subject examination federal state local tax authority tax examination complex tax authority disagree treatment item report require year resolve liability establish possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense liability represent reasonable provision taxis ultimately expect pay need adjusted time information know effect change estimate related contingent tax liability include effective tax rate reconciliation reconciliation begin end gross unrecognized tax benefit follow year end december dollar million balance begin year gross addition tax position relate current year gross reduction tax position relate current year gross addition tax position relate prior year gross reduction tax position relate prior year settlement reduction tax position relate lapse statute cumulative translation adjustment balance end year uncertain tax benefit reduce deferred tax asset extent uncertainty directly relate asset recognize current non current foreign income taxis payable unrecognized tax benefit recognize impact effective tax rate million million million december respectively gross addition tax position year end december include million tax reserve relate transfer international unit mead johnson prior ipo splitoff transaction recognize discontinued operation gross reduction tax position year end december include million liability relate mead johnson accrue interest penalty payable unrecognized tax benefit include current noncurrent foreign income taxis payable accrue interest relate unrecognized tax benefit million million million december respectively accrue penalty relate unrecognized tax benefit million million million december respectively interest penalty relate unrecognized tax benefit include income tax expense interest unrecognize tax benefit expense million million benefit million penalty unrecognize tax benefit expense million million benefit million bm currently examination number tax authority include major tax jurisdiction list table propose adjustment tax issue transfer price certain tax credit deductibility certain expense bms estimate reasonably possible total unrecognized tax benefit december decrease range approximately million million month result settlement certain tax audits event expect change unrecognized tax benefit primarily settlement related involve payment additional taxis adjustment certain defer taxis andor recognition tax benefit bms anticipate reasonably possible new issue raise tax authority require increase balance unrecognized tax benefit estimate increase reasonably time bms believe adequately provide open tax year tax jurisdiction follow summary major tax jurisdiction tax authority assert additional taxis base tax year currently audit subsequent year likely audit canada france germany italy mexico note earning share year end december amount million share datum basic eps calculation income continue operation attributable bms earning attributable unvested restricted share income continue operation attributable bms common shareholder net earning discontinue operation attributable bms eps numerator basic eps denominator basic average common share outstanding ep basic continue operation discontinue operation net earning eps numerator diluted income continue operation attributable bms earning attributable unvested restricted share income continue operation attributable bms common shareholder net earning discontinue operation attributable bms eps numerator diluted eps denominator diluted average common share outstanding contingently convertible debt common stock equivalent incremental share attributable sharebased compensation plan average common share outstanding common share equivalent eps diluted continue operation discontinue operation net earning net earning discontinue operation eps calculation net earning discontinue operation attributable bms earning attributable unvested restricted share net earning discontinue operation attributable bms ep calculation antidilutive weightedaverage equivalent share stock incentive plan note financial instrument financial instrument include cash cash equivalent marketable security account receivable payable debt instrument derivative short term maturity carrying receivables account payable approximate fair value bms exposure market risk change currency exchange rate interest rate result certain derivative financial instrument available costeffective basis hedge underlie economic exposure instrument qualify cash flow net investment fair value hedge meet certain criterion include effectiveness offset hedge exposure change fair value derivative qualify hedge accounting recognize earning occur derivative financial instrument trading purpose counterparty credit risk consider overall fair value measurement effect credit risk derivative liability position counterparty credit risk monitor ongoing basis mitigate limiting amount outstanding individual counterparty utilize conventional derivative financial instrument enter agreement counterpartie meet high credit quality standard consolidate financial statement materially impact counterparty fail perform accord term agreement term agreement post collateral require party derivative asset liability position fair value measurement fair value financial instrument classify follow category level input utilize nonbinde quote price unadjuste active market accessible measurement date identical asset liability fair value hierarchy give high priority level input instrument include treasury bill government agency security level input utilize observable price similar instrument nonbinde quote price identical similar instrument market active observable input corroborate market datum substantially term asset liability instrument include corporate debt security commercial paper federal deposit insurance corporation fdic insured debt security certificate deposit money market fund foreign currency forward contract interest rate swap contract level derivative instrument value london interbank offer rate libor euro interbank offer rate euribor yield curve credit valuation adjustment observable forward foreign exchange rate report date valuation derivative contract fluctuate considerably periodtoperiod volatility underlie foreign currency underlie interest rate drive market condition duration contract credit adjustment volatility significant impact valuation interest rate swap change credit rating credit default swap spread bms counterpartie level unobservable input little market datum available valuation model ars frs portfolio base expect cash flow stream collateral value include assessment counterparty credit quality default risk underlie security discount rate overall capital market liquidity majority ar private placement security longterm nominal maturity rate standard poor december primarily represent interest insurance securitization fair value determine internally develop valuation base indicative bid receive underlying asset security evidence fair value current lack active market frs general lack transparency underlie asset qualitative analysis rely value frs include discussion broker fund manager default risk underlie security overall capital market liquidity availableforsale security cash equivalent follow table summarize availableforsale security december unrealize unrealized gain loss amortize accumulate accumulate fair fair value dollar million cost oci oci value level level level december marketable security certificate deposit corporate debt security commercial paper treasury bill fdic insure debt security auction rate security ar float rate security frs total marketable security december marketable security certificate deposit corporate debt security commercial paper fdic insure debt security treasury bill government agency security auction rate security ar float rate security frs total marketable security follow table summarize classification availableforsale security consolidate balance sheet december dollar million current marketable security noncurrent marketable security total marketable security money market fund security aggregate million million december respectively include cash cash equivalent value level input cash cash equivalent maintain foreign currency million december subject currency rate risk december million noncurrent available sale corporate debt security treasury bill fdic insure debt security float rate security mature year auction rate security mature year follow table summarize activity financial asset utilize level fair value measurement fair value january settlement unrealize gainslosse fair value december qualifying hedge nonqualifye derivative follow summarize fair value outstanding derivative december december fair value fair value dollar million balance sheet location notional level notional level derivative designate hedge instrument interest rate swap contract asset foreign currency forward contract asset foreign currency forward contract accrue expense cash flow hedge foreign currency forward contract primarily utilize hedge forecast intercompany inventory purchase transaction certain foreign currency forward contract designate cash flow hedge effective portion change fair value temporarily report accumulate oci recognize earning hedge item affect earning december significant outstanding foreign currency forward contract primarily attribute euro japanese yen foreign currency forward contract notional million million respectively net gain foreign currency forward contract qualify cash flow hedge accounting expect reclassify cost product sell year include million pretax gain reclassify month cash flow hedge accounting discontinue forecast transaction long probable occur originally forecast date day hedge long effective assessment determine derivative designate qualifying hedge highly effective offset change cash flow hedge item perform inception quarterly basis ineffective portion change fair value include current period earning earning impact relate discontinued cash flow hedge hedge ineffectiveness significant net investment hedge nonus dollar borrowing million million designate hedge foreign currency exposure net investment certain foreign affiliate borrowing designate net investment hedge recognize long term debt effective portion foreign exchange gain loss remeasurement debt recognize foreign currency translation component accumulate oci relate offset long term debt fair value hedge fixedtofloate interest rate swap contract designate fair value hedge interest rate risk management strategy create appropriate balance fix float rate debt swap underlie debt benchmark risk hedge record fair value effective interest rate pay fixedtofloate interest rate swap onemonth libor december plus interest rate spread range underlying swap terminate prior maturity fair value basis adjustment underlie debt instrument amortize earning reduction interest expense remain life debt fixedtofloate interest rate swap contract execute convert million notional debenture million notional debenture fix rate debt variable rate debt fixedtofloate interest rate swap contract execute convert million notional note notional note fix rate debt variable rate debt contract qualify fair value hedge debt instrument fixedtofloate interest rate swap contract billion notional billion notional terminate generate total proceed million include accrue interest million fixedtofloate interest rate swap contract million notional million notional terminate generate total proceed million include accrue interest million million notional fixedtofloate interest rate swap contract terminate generating proceed million include accrue interest million nonqualifye foreign exchange contract foreign currency forward contract offset exposure foreign currencydenominate monetary asset liability earning primary objective contract protect dollar value foreign currencydenominate monetary asset liability earning effect volatility foreign exchange rate occur prior receipt settlement dollar contract designate hedge adjust fair value incomeexpense occur substantially offset change fair value underlie foreign currency denominate monetary asset liability earning effect nonqualifye hedge earning significant year end december shortterm borrowing longterm debt shortterm borrowing include december dollar millions bank draft shortterm borrowing total longterm debt include december dollar million principal value note euro note euro note note note note debenture debenture debenture othermature subtotal adjustment principal value fair value interest rate swap unamortize basis adjustment swap termination unamortized bond discount total include debt million float rate convertible senior debenture redeem holder par september fundamental change ownership occur debenture callable par time company debenture current conversion price equal conversion rate share principal subject certain antidilutive adjustment february mead johnson enter threeyear syndicate revolve credit facility agreement fourth quarter mead johnson borrow million revolve credit facility issue note total billion proceed repay certain intercompany debt prior splitoff principal value longterm debt obligation million december million million remain million fair value longterm debt million million december respectively estimate base quote market price similar debt instrument fair value shortterm borrowing approximate carry value short maturity debt instrument debt repurchase activity follow dollar million principal repurchase price notional interest rate swap terminate swap termination proceed total gainloss interest payment million million net amount related interest rate swap contract september company replace billion revolve credit facility new billion year revolve credit facility syndicate lender extendable anniversary date consent lender financial covenant new facility borrowing outstanding revolve credit facility december december million financial guarantee provide form standby letter credit performance bond standby letter credit issue financial institution support guarantee bms affiliate obligation performance bond issue support range ongoing operating activity include sale product hospital foreign ministry health bond custom duty value add tax guarantee relate miscellaneous legal action significant majority outstanding financial guarantee expire year expect fund note receivables receivables include december dollar million trade receivable allowance net trade receivables alliance partner receivables prepaid refundable income taxis miscellaneous receivables receivables receivables net deferred income relate alliance partner recognition income result alliance partner receivables defer income reduce million million december respectively additional information alliance partner note alliance collaboration nonus receivables sell nonrecourse basis million million million aggregate receivable pharmaceutical wholesaler represent total trade receivables december respectively change allowance bad debt chargeback cash discount follow year end december dollar million balance begin year provision utilization discontinue operation balance end year note inventory inventory include december dollar million finish good work process raw packaging material inventory inventory expect remain onhand year include noncurrent asset million include million capitalize cost subject regulatory approval prior sell december million december status regulatory approval process probability future sale consider assess recoverability cost note property plant equipment property plant equipment include december dollar million land building machinery equipment fixture construction progress gross property plant equipment accumulate depreciation property plant equipment depreciation expense million million million million include discontinue operation capitalize interest million million note goodwill intangible asset change carry goodwill follow dollar millions balance january zymogenetics acquisition balance december amira acquisition balance december include outofperiod adjustment record correct purchase price allocation september medarex acquisition million contingent milestone payment prior acquisition medarex purchase price adjustment decrease intangible asset million increase defer tax asset million goodwill million effect adjustment material current prior period intangible asset include december december gross net gross net estimate carry accumulate carrying carry accumulate carry dollar million useful life amortization amortization license year technology year capitalize software year total finitelive intangible asset iprd total intangible asset billion iprd reclassify technology approval yervoy million iprd reclassify license license compound performance obligation change intangible asset follow dollar million intangible asset carry january capitalize software addition acquisition mead johnson splitoff amortization license technology amortization capitalize software impairment charge intangible asset carry december amortization expense include discontinue operation million amortization expense intangible asset expect million million million million million million note accrue expense accrue expense include december dollar million employee compensation benefit royaltie accrue research development restructuringcurrent pension postretirement benefit accrue litigation total accrue expense note sale rebate return accrual reduction trade receivable accrue rebate return liability follow december dollar million chargeback relate government program cash discount reduction trade receivables manage healthcare rebate contract discount medicaid rebate sale return adjustment accrue rebate return note deferred income defer income include december dollar millions upfront milestone licensing receipt atripla defer revenue gain saleleaseback transaction total defer income current portion noncurrent portion upfront milestone licensing receipt amortize expect life product note alliance collaboration information pertain revenue recognition transaction alliance collaboration defer gain saleleaseback transaction amortize remain lease term relate facility million million million note equity capital common stock excess treasury stock par value retain noncontrolle dollar share million share par value stock earning share cost interest balance january net earning attributable bms cash dividend declare mead johnson ipo adjustment mead johnson net asset transfer mead johnson splitoff employee stock compensation plan net earning attributable noncontrolle interest comprehensive income attributable noncontrolle interest distribution balance december net earning attributable bms cash dividend declare stock repurchase program employee stock compensation plan net earning attributable noncontrolle interest distribution balance december net earning attributable bms cash dividend declare stock repurchase program employee stock compensation plan net earning attributable noncontrolle interest comprehensive income attributable noncontrolle interest distribution balance december treasury stock recognize cost reacquire share treasury share acquire mead johnson splitoff recognize fair value stock splitoff date share issue treasury recognize utilize firstin firstout method board director authorize repurchase billion common stock repurchase open market private transaction include repurchase plan establish accordance rule b securities exchange act amend stock repurchase program expiration date suspend discontinue time noncontrolle interest primarily relate partnership sanofi territory cover america net sale plavix net earning attributable noncontrolle interest present net taxis million million million consolidated statement earning correspond increase provision income taxis distribution partnership profit sanofi sanofis fund ongoing partnership operation occur routine basis activity include pretax income distribution relate partnership net earning noncontrolle interest include discontinue operation million accumulate balance relate component comprehensive incomeloss oci net taxis follow derivative pension accumulate foreign qualifying currency effective postretirement available comprehensive dollar million translation hedge benefit sale security incomeloss balance january comprehensive incomeloss balance december comprehensive incomeloss balance december comprehensive incomeloss balance december note pension postretirement postemployment liability company certain subsidiary sponsor define benefit pension plan define contribution plan termination indemnity plan regular fulltime employee principal define benefit pension plan bristolmyers squibb retirement income plan cover employee represent approximately consolidated pension plan asset obligation fund policy contribute minimum require employee retirement income security act erisa plan benefit base primarily participant year credit service final average compensation plan asset consist principally equity fixedincome securities comprehensive medical group life benefit provide substantially retiree elect participate comprehensive medical group life plan medical plan contributory contribution adjust periodically vary date retirement life insurance plan noncontributory plan asset consist principally equity fixedincome security similar plan exist employee certain country outside net periodic benefit cost define benefit pension postretirement benefit plan include pension benefit benefit dollar million service cost benefit earn year interest cost project benefit obligation expect return plan asset amortization prior service costbenefit amortization net actuarial loss curtailment settlement special termination benefit total net periodic benefit cost continue operation discontinue operation total net periodic benefit cost net actuarial loss prior service cost million expect amortize accumulate oci net periodic benefit cost pension postretirement benefit plan retirement income plan plan amend june amendment eliminate credit future benefit relate service effective december salary increase continue consider additional fiveyear period determine benefit obligation relate prior service plan amendment account curtailment result applicable plan asset obligation remeasure remeasurement result million reduction accumulate oci million net taxis correspond decrease fund status plan curtailment update plan asset valuation change discount rate curtailment charge million recognize expense second quarter remain unrecognize prior service cost addition participant reclassify inactive benefit plan purpose actuarial gain loss amortize expect weightedaverage remain life plan participant year connection plan amendment contribution principal define contribution plan puerto rico increase effective january net impact action expect reduce future retiree benefit cost future cost continue subject market condition factor include actual expect plan asset performance interest rate fluctuation lumpsum benefit payment certain plan asset relate obligation transfer retirement income plan plan new plan sponsor mead johnson active mead johnson participant result million reduction accumulate oci million net taxis quarter correspond decrease fund status plan update plan asset valuation change discount rate change define benefit postretirement benefit plan obligation asset fund status amount recognize consolidated balance sheet follow pension benefit benefit dollar million benefit obligation begin year service costbenefit earn year interest cost plan participant contribution curtailment settlement plan amendment actuarial loss retiree drug subsidy benefit pay special termination benefit exchange rate lossesgain benefit obligation end year fair value plan asset begin year actual return plan asset employer contribution plan participant contribution settlement retiree drug subsidy benefit pay exchange rate gainslosse fair value plan asset end year fund status assetsliabilitie recognize asset accrue expense pension postretirement liability fund status recognize accumulate comprehensive loss net actuarial loss net obligation adoption prior service costbenefit total accumulate benefit obligation define benefit pension plan million million december respectively additional information relate pension plan follow dollar million pension plan project benefit obligation excess plan asset project benefit obligation fair value plan asset pension plan accumulate benefit obligation excess plan asset accumulate benefit obligation fair value plan asset actuarial assumption weightedaverage assumption determine benefit obligation december follow pension benefit benefit discount rate rate compensation increase weightedaverage actuarial assumption determine net periodic benefit cost year end december follow pension benefit benefit discount rate expect longterm return plan asset rate compensation increase yield high quality corporate bond match duration benefit obligation determine discount rate citigroup pension discount curve develop discount rate plan factor consider develop expect return plan asset include longterm historical return input external advisor individual asset class return forecast develop base market condition example priceearning level yield longterm growth expectation expect longterm rate return weightedaverage target asset allocation individual asset class historical longterm actual annualize return pension plan follow year year year pension postretirement liability increase billion december corresponding charge comprehensive income result lower expect return plan asset million actuarial loss attribute benefit obligation million actuarial loss result prevail equity fix income market condition reduction interest rate expect return plan asset determine expect rate return calculate value asset refer marketrelated value marketrelate value exceed fair value plan asset million december fair value plan asset exceed marketrelated value million december difference assume actual return amortize marketrelated value straightline basis year period gain loss result change actuarial assumption change discount rate difference assume actual experience difference actual expect return plan asset gain loss difference amortize market relate value amortize extent exceed high marketrelated value project benefit obligation respective plan result approximately million related pension benefit expect amortized majority remain actuarial loss amortize life expectancy plan participant plan expect remain service period plan assume healthcare cost trend rate december follow healthcare cost trend rate assume year rate cost trend rate assume decline ultimate trend rate year rate reach ultimate trend rate assume healthcare cost trend rate effect amount report healthcare plan onepercentagepoint change assume healthcare cost trend rate follow effect percentage percentage dollar million point increase point decrease effect total service interest cost effect postretirement benefit obligation plan asset fair value pension postretirement plan asset asset category december follow december december dollar million level level level total level level level total equity fund equity security fix income fund venture capital limited partnership government mortgage back security corporate debt security shortterm investment fund treasury agency security insurance contract event drive hedge fund collateralize mortgage obligation bond state municipal bond asset back security real estate cash cash equivalent total plan asset fair value investment valuation policy investment class follow level input utilize quote price unadjuste active market accessible measurement date identical asset liability fair value hierarchy give high priority level input instrument include equity security equity fund fix income fund publicly trade national security exchange treasury agency security cash cash equivalent cash cash equivalent highly liquid investment original maturity month time purchase recognize cost approximate fair value pende trade sale purchase include cash cash equivalent final settlement level input include observable price similar instrument quote price identical similar instrument market active observable input corroborate market datum substantially term asset liabilitie equity fund fix income fund event drive hedge fund shortterm investment fund classify level fair value hierarchy value net asset value share hold year end corporate debt security government mortgage back security collateralize mortgage obligation bond asset back security treasury agency security state municipal bond real estate interest classify level fair value hierarchy value utilize observable price similar instrument quote price identical similar instrument market active level unobservable input little market datum available equity fund venture capital limited partnership investment classify level fair value hierarchy value estimate fair value estimate fair value base fair value underlie investment value cost plus minus accumulate earning loss approximate fair value insurance contract interest carry contract value approximate estimate fair value base fair value underlie investment insurance company insurance contract hold certain foreign pension plan valuation model corporate debt security collateralize mortgage obligation bond asset back security classify level fair value hierarchy base estimate bid broker thirdparty vendor source utilize expect cash flow stream collateral value include assessment counterparty credit quality default risk discount rate overall capital market liquidity follow summarize activity financial asset utilize level fair value measurement venture capital limited insurance dollar million partnership contract total fair value january purchase sale settlement realize lossesgain unrealized gainslosse fair value december purchase sale settlement realize lossesgain unrealized gainslosse fair value december investment strategy emphasize equity order achieve higher expect return low expense require cash contribution longterm target asset allocation public equity international private equity fix income maintain pension plan investment diversify major asset category approximately pension plan equity investment actively manage venture capital limited partnership typically value month lag bristolmyers squibb company common stock represent plan asset december contribution contribution pension plan million million million include million mead johnson contribution pension plan expect approximate million million contribute january contribution international pension plan million million million contribution international plan expect range million million estimate future benefit payment pension dollar million benefit benefit year saving plan principal define contribution plan bristolmyer squibb saving investment program contribution base employee contribution level company match qualified define contribution plan amend allow increase matching additional company contribution effective expense relate plan million million million post employment benefit plan postemployment liability longterm disability benefits million december expense relate benefit million million termination indemnity plan statutory termination obligation europe recognize undiscounted basis assume employee termination measurement date liability recognize obligation million december note employee stock benefit plan shareholder approve stock award incentive plan plan replace stock incentive plan expire share common stock reserve issuance pursuant stock plan option conversion prefer stock million december share available grant active plan adjust combination plan million december share stock option exercise share unit vest issue treasury stock share actually deliver participant connection award restriction lapse reduce number share reserve share tender prior year pay purchase price option share previously utilize satisfy withholding tax obligation exercise continue available reserve executive officer key employee grant option purchase common stock market price date option grant option generally exercisable ratably year maximum term year additionally plan provide grant stock appreciation right grantee surrender exercisable right receive common stock andor cash measure excess market price common stock option exercise price common stock grant key employee subject restriction continuous employment restriction expire year period date grant compensation expense recognize vest period stock unit right receive stock end specify vest period voting right begin market share unit grant certain executive vest market share unit condition continuous employment vest date payout factor equal payout factor share price vest date divide share price award date maximum share price payout factor calculate average closing price grant vest date trading day immediately precede grant vest date vest occur ratably year longterm performance award year cycle deliver form target number performance share unit number share ultimately issue calculate base actual performance compare earning target performance criterion establish begin performance period award annual goal maximum payout threshold target meet performance period payment plan annual period vest occur end year period stockbase compensation expense base award ultimately expect vest recognize vest period forfeiture estimate base historical experience time grant revise subsequent period actual forfeiture differ estimate stockbase compensation expense follow year end december dollar million stock option restrict stock market share unit longterm performance award total stockbase compensation expense continue operation discontinue operation total stockbase compensation expense defer tax benefit relate stockbase compensation expense sharebase compensation activity follow longterm stock option restrict stock unit market share unit performance award weight number weight number weight number weight number average average average average option exercise price nonveste grantdate nonveste grantdate nonveste grantdate share thousand outstanding share awards fair value award fair value award fair value balance january grant releasedexercised adjustment actual payout forfeit balance december total compensation cost relate sharebased payment award recognize weightedaverage period award expect recognize december follow longterm stock restrict market performance dollar million option stock unit share unit awards unrecognize compensation cost expect weightedaverage period year compensation cost recognize additional information relate sharebased compensation award summarize follow amount million share datum weightedaverage grant date fair value share stock option restrict stock unit market share unit longterm performance award fair value option award vest year stock option restrict stock unit market share unit longterm performance award total intrinsic value stock option exercise year follow table summarize significant range outstanding exercisable option december amount million share datum option outstanding option exercisable weighted weight average weighted average weight remain average remain average number contractual exercise aggregate contractual exercise aggregate outstanding life price intrinsic number life price intrinsic range exercise price thousand year share value exercisable year share value aggregate intrinsic value precede table represent total pretax intrinsic value base close stock price december fair value assumption fair value stock option estimate grant date blackschole option pricing model stock option service condition model apply multiple input variable determine probability satisfy market condition option service market condition follow weightedaverage assumption valuation expect volatility riskfree interest rate dividend yield expect life yr expect volatility assumption require blackschole model derive calculate year historical volatility weighting equally derive imply volatility blend historical imply volatility approach expect volatility believe representative future stock price trend historical volatility riskfree interest rate assumption base treasury yield curve effect grant date dividend yield assumption base historical expect dividend payout expect life stock option represent weightedaverage period stock option remain outstanding derive output latticebinomial model expect life impact underlying assumption calibration model model assume employee exercise behavior function option remain vested life extent option inthemoney model estimate probability exercise function variable base historical exercise cancellation prior option grant fair value restrict stock unit longterm performance award determine base closing trading price company common stock grant date begin fair value performance share unit grant discount participate dividend fair value performance share unit grant prior discount riskfree interest rate date grant participate dividend fair value market share unit estimate date grant model apply multiple input variable determine probability satisfy market condition model use follow input variable expect volatility riskfree interest rate dividend yield expect volatility base year historical volatility level company common stock current imply volatility fouryear riskfree interest rate derive federal reserve base market share unit contractual term expect dividend yield base historical dividend payment note lease minimum rental commitment noncancelable operating lease primarily real estate motor vehicle effect december follow year end december dollar million later year total minimum rental commitment operate lease expense million million million million include discontinue operation sublease income material year end december note legal proceeding contingency company certain subsidiary involve lawsuit claim government investigation legal proceeding arise ordinary course business company recognize accrual contingency probable liability incur loss reasonably estimate matter involve patent infringement antitrust security pricing sale marketing practice environmental commercial health safety matter consumer fraud employment matter product liability insurance coverage litigation expense net include million insurance reimbursement prior litigation offset additional reserve certain average wholesale price awp litigation million security litigation settlement legal proceeding material company believe material describe company believe substantial defense matter assurance increase scope pende matter future lawsuit claim government investigation legal proceeding material note company unable assess outcome respective litigation able provide estimate range potential loss furthermore failure enforce patent right likely result substantial decrease respective product sale generic competition intellectual property plavix litigation patent infringement litigation apotex relate matter previously disclose company territory partnership alliance sanofi plaintiff pende patent infringement lawsuit institute united states district court southern district new york district court entitle sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceutical hold partnership v apotex suit base patent patent composition matter patent disclose claim thing hydrogen sulfate salt clopidogrel medicine available company plavix previously report district court uphold validity enforceability patent maintain main patent protection plavix life patent term expire district court rule apotexs generic clopidogrel bisulfate product infringe patent permanently enjoin apotex engage activity infringe patent include market generic product patent expire apotex appeal district court decision december united states court appeal federal circuit circuit court affirm district court rule sustain validity patent apotex file petition circuit court rehear en banc march circuit court deny apotexs petition case remand district court proceeding relate damage july apotex file petition writ certiorari supreme court request supreme court review circuit court decision november supreme court deny petition decline review circuit court decision december company file motion district court summary judgment damage january apotex file motion seek stay ongoing damage proceeding pende outcome reexamination plavix patent patent trademark office pto describe april district court deny apotexs motion stay proceeding october district court grant company summary judgment motion award million damage plus cost interest apotex appeal damage award validity patent claim clopidogrel bisulfate finally judicially determine favor company maintain patent protection market exclusivity plavix include additional sixmonth pediatric exclusivity period october circuit court uphold million damage award reverse district court award prejudgment interest february company receive payment million damage award plus cost postjudgment interest bms receive million previously disclose company territory partnership alliance sanofi plaintiff additional patent infringement lawsuit dr reddys laboratories inc dr reddys laboratories ltd dr reddys teva pharmaceuticals usa inc teva cobalt pharmaceuticals inc cobalt watson pharmaceuticals inc watson laboratories inc watson sun pharmaceuticals sun lawsuit dr reddys teva cobalt relate patent dr reddys sign consent judgment favor sanofi bms concede validity infringement patent previously report patent infringement action teva cobalt stay pende resolution apotex litigation party action agree bind outcome litigation apotex consequently july district court enter judgment cobalt teva permanently enjoin cobalt teva engage activity infringe patent patent expire cobalt teva file appeal july circuit court issue mandate teva appeal bind teva decision apotex litigation august cobalt consent entry judgment appeal agree bind circuit court decision apotex litigation lawsuit watson file october base patent patent disclose claim particular crystalline polymorph form hydrogen sulfate salt clopidogrel market plavix december court permit watson pursue declaratory judgment counterclaim respect patent january court approve party stipulation stay case pende outcome trial apotex matter bms watson enter stipulation dismiss case april pharmastar file request inter part reexamination patent pto pto grant request july july pto vacate reexamination proceeding lawsuit sun file july base infringement patent patent respect patent sun agree bind outcome apotex litigation respect patent party settle december case dismiss additionally november apotex file lawsuit new jersey superior court entitle apotex inc et al v sanofiaventis et al seek payment million plus interest relate breakup march propose settlement agreement april new jersey superior court grant company crossmotion summary judgment motion deny apotexs motion summary judgment apotex appeal decision possible time determine outcome appeal new jersey superior court decision january apotex file lawsuit florida state court broward county allege breach contract relate party propose settlement agreement discovery ongoing plavix litigation international plavix australia previously disclose sanofi notify august genrx proprietary limited genrx obtain regulatory approval application clopidogrel bisulfate mg tablets australia genrx subsidiary apotex change apotex august apotex file application federal court australia seek revocation sanofis australian patent case nsd sanofi file counterclaims infringement seek injunction september australian court grant sanofis injunction subsidiary company subsequently add party proceeding february second company spirit pharmaceuticals pty ltd file revocation suit patent case consolidate apotex case trial occur april august federal court australia hold claim patent cover clopidogrel bisulfate hydrochloride hydrobromide taurocholate salt valid federal court hold process claim pharmaceutical composition claim claim direct clopidogrel pharmaceutically acceptable salt invalid company sanofi file notice appeal court federal court australia court appeal hold invalidity claim cover clopidogrel pharmaceutically acceptable salt process claim pharmaceutical composition claim stay federal court rule apotex file notice appeal appeal hold validity clopidogrel bisulfate hydrochloride hydrobromide taurocholate claim hearing appeal occur february september federal court australia hold claim patent invalid november company sanofi apply high court australia high court special leave appeal judgment court march high court deny company sanofis request hear appeal court decision case remand federal court proceeding relate damage expect damage material company plavix eu previously disclose yes pharmaceutical development service gmbh yes pharmaceutical file application marketing authorization germany alternate salt form clopidogrel application rely datum study originally conduct sanofi bms plavix subject datum protection eu sanofi bms file action yes pharmaceutical partner administrative court cologne object marketing authorization matter currently pende specific marketing authorization withdraw market plavix canada apotex inc april apotex file impeachment action sanofi federal court canada allege sanofis canadian patent patent invalid patent cover clopidogrel bisulfate patent issue prohibition action canada previously disclose canadian federal court ottawa reject apotexs challenge patent hold asserted claim novel obvious infringe grant sanofis application order prohibition minister health apotex preclude approval apotexs abbreviate new drug submission patent expire august decision affirm appeal federal court appeal supreme court canada june sanofi file defense impeachment action file suit apotex infringement patent trial complete june december federal court issue decision patent invalid sanofi appeal decision generic company enter market intellectual property litigation abilify previously disclose otsuka file patent infringement action teva barr pharmaceuticals inc barr sandoz inc sandoz synthon laboratories inc synthon sun pharmaceutical sun zydus pharmaceuticals usa inc zydus apotex relate patent patent cover aripiprazole expire april include additional sixmonth pediatric exclusivity period aripiprazole comarketed company otsuka abilify nonjury trial district court district new jersey nj district court tevabarr apotex complete august november nj district court uphold validity enforceability patent maintain main patent protection abilify april nj district court rule defendant generic aripiprazole product infringe patent permanently enjoin engage activity infringe patent include market generic product patent include sixmonth pediatric extension expire sandoz synthon sun zydus bind nj district court decision december tevabarr apotex appeal decision court appeal federal circuit oral argument hold february possible time determine outcome appeal nj district court decision otsuka prevail appeal generic competition likely result substantial decrease sale abilify material adverse effect result operation cash flow material financial condition atripla april teva file anda manufacture market generic version atripla atripla single tablet threedrug regimen combine company sustiva gilead truvada time company patent right cover sustivas composition matter method use challenge teva send gilead paragraph iv certification letter challenge orange book list patent atripla atripla product joint venture company gilead gilead file patent infringement action teva district court southern district new york sdny january company receive notice teva amend anda challenge additional orange book list patent atripla march company merck sharp dohme corp file patent infringement action teva sdny relate patent claim crystalline polymorph form efavirenz march gilead file patent infringement action teva sdny relate orange book list patent atripla discovery matter ongoing possible time reasonably assess outcome lawsuit impact company baraclude august teva file anda manufacture market generic version baraclude company receive paragraph iv certification letter teva challenge orange book list patent baraclude patent september company file patent infringement lawsuit delaware district court teva infringement list patent covering baraclude trigger automatic month stay approval tevas anda discovery matter ongoing possible time reasonably assess outcome lawsuit impact company trial currently schedule october sprycel september apotex file anda manufacture market generic version sprycel company receive paragraph iv certification letter apotex challenge orange book list patent sprycel include composition matter patent november company file patent infringement lawsuit district court district new jersey apotex infringement orange book list patent cover sprycel trigger automatic month stay approval apotexs anda october company receive paragraph iv notice letter apotex inform company seek approval generic version mg mg dosage strength sprycel challenge orange book list patent november bms file patent infringement suit apotex mg mg dosage strength new jersey district court case consolidate suit file november discovery matter ongoing possible time reasonably assess outcome lawsuit impact company sustiva eu january teva obtain european marketing authorization efavirenz teva mg tablets february company merck sharp dohme merck file lawsuit request injunction teva netherlands germany uk infringement mercks european patent supplementary protection certificate expire november possible time reasonably assess outcome lawsuit impact company general commercial litigation clayworth litigation previously disclose company number pharmaceutical manufacturer name defendant action file california state superior court oakland james clayworth et al v bristolmyers squibb company et al allege defendant conspire fix price pharmaceutical agree charge drug charge outside particularly canada assert claim california cartwright act unfair competition law plaintiff sought treble monetary damage injunctive relief relief december court grant company manufacturer motion summary judgment base passon defense judgment enter favor defendant july judgment favor defendant affirm california court appeals july california supreme court reverse court appeal judgment matter remand superior court proceeding march defendant motion summary judgment grant judgment enter favor defendant plaintiff appeal decision pricing sale promotional practice litigation investigation abilify federal subpoena january company receive subpoena united states attorney office southern district new york request information relate thing sale marketing abilify possible time assess outcome matter potential impact company abilify state attorney general investigation march company receive letter delaware attorney general office advise multistate coalition investigate certain abilify marketing practice violate respective state consumer protection statute possible time reasonably assess outcome investigation potential impact company awp litigation previously disclose company number pharmaceutical manufacturer defendant number private class action suit bring attorney general state action plaintiff allege defendant cause average wholesale price awps product inflate injure government program entity person reimburse prescription drug base awps company defendant state attorney general suit pende state court country begin august company defendant trial commonwealth court pennsylvania commonwealth court bring commonwealth pennsylvania september jury issue verdict company find company liable fraudulent negligent misrepresentation commonwealth court judge issue decision pennsylvania consumer protection claim jury find company liable million enjoin company contribute provision inflate awps company move vacate decision commonwealth move judgment notwithstanding verdict court deny company commonwealth appeal decision pennsylvania supreme court qui tam litigation march company serve unseal qui tam complaint file sale representative california superior court county los angeles california department insurance elect intervene lawsuit complaint allege company pay kickbacks california providers pharmacy violation california insurance frauds prevention act cal in code possible time reasonably assess outcome lawsuit impact company product liability litigation company party product liability lawsuit previously disclose addition lawsuit company face unfiled claim involve product plavix previously disclose company certain affiliate sanofi defendant number individual lawsuit federal state court claim personal injury damage allegedly sustain plavix currently claim file primarily state federal court new jersey illinois new york pennsylvania company execute tolling agreement respect unfiled claim potential additional plaintiff possible time reasonably assess outcome lawsuit potential impact company reglan company number defendant numerous lawsuit behalf approximately plaintiff claim personal injury allegedly sustain reglan brand generic drug metoclopramide product indicate gastroesophageal reflux certain gastrointestinal disorder company generic subsidiary apothecon inc distribute metoclopramide tablet manufacture party possible time reasonably assess outcome lawsuit potential impact company hormone replacement therapy company number defendant masstort litigation plaintiff allege thing hormone therapy product include hormone therapy product manufacture company estrace estradiol delestrogen ovcon cause breast cancer stroke blood clot cardiac injury woman defendant aware risk fail warn consumer company agree resolve claim approximately plaintiff december company remain defendant approximately actively pende lawsuit federal state court company hormone therapy product sell company january august environmental proceeding previously report company party environmental proceeding matter responsible state federal foreign law include comprehensive environmental response compensation liability act cercla certain cost investigate andor remediate contamination result past industrial activity company current site waste disposal reprocess facility operate thirdpartie cercla matter respect cercla matter company responsible state federal foreign law company typically estimate potential cost base information obtain environmental protection agency counterpart state foreign agency andor study prepare independent consultant include total estimate cost site expect costshare potentially responsible party company accrue liability probable reasonably estimable company estimate share future cost site million december represent sum good estimate good estimate reasonably estimate minimal probable range cost take account potential recovery party new brunswick facility environmental personal injury lawsuit lawsuit file company new jersey superior court behalf current resident new brunswick nj live live adjacent company new brunswick facility complaint allege personal injury damage result allege soil groundwater contamination property stem historical operation new brunswick facility claim medical monitoring portion complaint assert claim allege property damage october new jersey supreme court grant mass tort status case transfer new jersey superior court atlantic county centralize case management purpose company intend defend vigorously litigation discovery ongoing october additional case file new jersey superior court remove company federal court trenton nj plaintiff move remand case state court company oppose possible time reasonably assess outcome lawsuit potential impact company north brunswick township board education previously disclose october company contact counsel represent north brunswick nj board education boe site waste material er squibb son disposed fill material contain industrial waste heavy metal excess residential standard discover expansion project north brunswick township high school number neighbor residential property adjacent public park area january new jersey department environmental protection njdep send company information request letter possible waste disposal site company respond march boe township current owner school property park conduct jointly finance soil remediation work ground water investigation work work plan approve njdep ask company contribute cost company actively monitor cleanup project include cost date school board township assert claim company instead company local entity negotiate agreement attempt resolve matter informal mean avoid litigation central component agreement provision company interim funding help defray cleanup cost assure work interrupt company transmit interim funding payment december november party commence mediation late effort successful party move bind allocation process party expect conduct fact expert discovery follow formal evidentiary hearing write argument hearing likely schedule midtolate addition september township boe file suit party allege contribute waste material site company currently believe responsible additional amount interim payment total million transmit additional possible loss expect material proceeding italy investigation july public prosecutor florence italy italian prosecutor initiate criminal investigation company subsidiary italy bms italy allegation company relate allege activity employee leave company italian prosecutor request interim measure judicial administrator appoint temporarily run operation bms italy request pende florence court possible time assess outcome investigation potential impact company sec germany investigation previously disclose october sec notify company conduct informal inquiry activity certain company german pharmaceutical subsidiary employee andor agent october sec inform company inquiry formal sec inquiry encompass matter investigation german prosecutor munich germany resolve company understand inquiry concern potential violation foreign corrupt practice act company cooperate sec note subsequent event february bms complete acquisition outstanding share inhibitex inc inhibitex clinicalstage biopharmaceutical company focus develop product prevent treat infectious disease aggregate purchase price approximately billion acquisition relate cost expect approximate million include expense bms obtain inhibitexs lead asset inx oral nucleotide polymerase nsb inhibitor phase ii development treatment chronic hepatitis c infection program stage development preliminary purchase price allocation currently process purchase price expect allocate goodwill inx note select quarterly financial datum unaudite dollar million share datum quarter second quarter quarter fourth quarter year net sale gross margin net earning net earning attributable noncontrolle interest net earning attributable bms eps basic eps dilute dividend declare common share cash cash equivalent marketable security dollar million share datum quarter second quarter quarter fourth quarter year net sale gross margin net earning net earning attributable noncontrolle interest net earning attributable bms eps basic eps dilute dividend declare common share cash cash equivalent marketable security earning share quarter add amount year period compute discrete basis marketable security include current noncurrent asset follow specify item affect comparability result dollar million quarter second quarter quarter fourth quarter year provision restructuring accelerate depreciation asset impairment shutdown cost pension curtailment settlement charge process standardization implementation cost gain sale product line business asset litigation chargesrecoverie upfront milestone licensing payment net iprd impairment product liability charge total income taxis item specify tax benefit decrease net earning relate release tax reserve specify prior period dollar million quarter second quarter quarter fourth quarter year provision restructuring impairment loss sale manufacturing operation accelerate depreciation asset impairment shutdown cost pension curtailment settlement charge process standardization implementation cost litigation chargesrecoverie upfront milestone licensing payment iprd impairment acquisition relate item product liability charge total income taxis item outofperiod tax adjustment specify tax charge decrease net earning relate tax charge additional taxable income earning foreign subsidiary previously consider permanently reinveste offshore report independent register public accounting firm board director shareholder bristolmyers squibb company audit accompany consolidated balance sheet bristolmyer squibb company subsidiary company december relate consolidated statement earning comprehensive income cash flow year period end december financial statement responsibility company management responsibility express opinion financial statement base audit conduct audits accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement audit include assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion opinion consolidate financial statement present fairly material respect financial position bristolmyer squibb company subsidiary december result operation cash flow year period end december conformity accounting principle generally accept united states america audit accordance standard public company accounting oversight board united states company internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission report date february express unqualified opinion company internal control financial reporting deloitte touche llp parsippany new jersey february item change disagreement accountant account financial disclosure item control procedure evaluation disclosure control procedure december management carry evaluation supervision participation chief executive officer chief financial officer effectiveness design operation disclosure control procedure term define exchange act rule ae base evaluation management conclude december disclosure control procedure effective management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting supervision participation management include chief executive officer chief financial officer management assess effectiveness internal control financial reporting december base framework internal controlintegrate framework issue committee sponsor organization treadway commission base assessment management conclude company internal control financial reporting effective december provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance united states generally accept accounting principle inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate deloitte touche llp independent register public accounting firm audit company financial statement include report issue report effectiveness company internal control financial reporting december include change internal control financial reporting change companys internal control financial reporting quarter end december materially affect reasonably likely materially affect company internal control financial reporting item b information report independent register public accounting firm board director shareholder bristolmyers squibb company audit internal control financial reporting bristolmyer squibb company subsidiary company december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission company management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion company internal control financial reporting base audit conduct audit accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk perform procedure consider necessary circumstance believe audit provide reasonable basis opinion company internal control financial reporting process design supervision company principal executive principal financial officer person perform similar function effect company board director management personnel provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting include possibility collusion improper management override control material misstatement error fraud prevented detect timely basis projection evaluation effectiveness internal control financial reporting future period subject risk control inadequate change condition degree compliance policy procedure deteriorate opinion company maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission audit accordance standard public company accounting oversight board united states consolidated financial statement company year end december report date february express unqualified opinion financial statement deloitte touche llp parsippany new jersey february iii item director executive officer registrant reference proxy statement file march respect director registrant incorporate reference hereof response information require item b information require item respect executive officer registrant include ia reliance general instruction g instruction item b regulation sk item executive compensation reference proxy statement file march respect executive compensation incorporate reference hereof response information require item item security ownership certain beneficial owner management relate stockholder matter reference proxy statement file march respect security ownership certain beneficial owner management incorporate reference hereof response information require item item certain relationship relate transaction reference proxy statement file march respect certain relationship relate transaction incorporate reference hereof response information require item item auditor fee reference proxy statement file march respect auditor fee incorporate reference hereof response information require item iv item